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CHAPTER I 
 
INTRODUCTION 
 
Overview 
Viruses are obligate intracellular pathogens that must adhere to and enter 
cells to initiate an infectious cycle. Receptors expressed on the host cell surface 
attach the virus to target cells and serve as a determinant of host range and 
tissue tropism. Since receptor engagement governs the susceptibility of cells to 
infection, insight into receptor utilization can enhance an understanding of more 
general principles of ligand-receptor interactions, shed light on the contribution of 
receptor engagement to disease, and potentially aid in the design of antiviral 
drugs and viral vectors.  
It is common for viruses to bind multiple receptors to facilitate efficient viral 
entry. Human immunodeficiency virus (HIV) binds primary receptor CD4 (1) and 
co-receptor CCR5 or CXCR4 (2, 3), adenovirus utilizes both coxsackie virus and 
adenovirus receptor (CAR) (4) and integrins during entry (5, 6), and mammalian 
orthoreoviruses, herein referred to as reoviruses, use sialylated glycans (7-10), 
junctional adhesion molecule A (JAM-A) (11, 12), integrins (13, 14), and Nogo 
receptor 1 (NgR1) (15). The contribution of individual receptors to viral disease is 
not completely understood.  
Reoviruses display serotype-dependent pathology, with serotype 1 (T1) 
strains causing hydrocephalus (16) and serotype 3 (T3) strains causing 
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encephalitis (17), but the basis for these serotype-specific differences is not 
known. T1 and T3 reoviruses engage the same known proteinaceous receptors 
(11, 15), yet they interact with distinct glycans. This observation suggests that 
differences in glycan utilization contribute to serotype-specific differences in 
tropism.  
This thesis describes results of experiments I conducted to understand the 
molecular basis of T1 reovirus-glycan interactions and define the contribution of 
glycan engagement to T1 reovirus-mediated disease. In Chapter 1, I present 
data identifying GM2 as a specific carbohydrate bound by T1 reovirus. In Chapter 
2, I show data that define residues in the T1 reovirus σ1 attachment protein 
required for functional GM2 engagement. In Chapter 3, I describe findings from in 
vivo experiments demonstrating that T1 reovirus-GM2 interactions influence 
hydrocephalus severity in mice. Taken together, these results establish a 
determinant of reovirus serotype-specific disease, deepen an understanding of 
the function of glycan binding in viral tropism, and may facilitate design of 
therapeutic reovirus vectors. 
 
Virus-Receptor Interactions 
Many viruses use cell-surface carbohydrates such as glycosaminoglycans 
(GAGS) (18-21), blood group antigens (22, 23), and sialylated glycans (7, 8, 24-
27) to facilitate attachment and entry. Some viruses, such as influenza virus, 
appear to engage sialic acid as a primary receptor (26), while others, such as 
reovirus, engage sialic acid as an initial adhesive event prior to binding a 
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proteinaceous attachment receptor, in a process known as adhesion 
strengthening (7, 11). Sialic acid is amongst the oldest known virus receptors 
(28), and many enveloped and nonenveloped viruses bind some form of sialic 
acid to facilitate entry. 
 
Sialic acid containing glycans are common virus receptors 
Sialic acid, also known as neuraminic acid, is a nine-carbon 
monosaccharide ubiquitously expressed in higher vertebrates (29). In the host, 
sialic acids function in cell-cell adhesion, cell signaling, especially within the 
immune system, and development (30, 31). Genetic defects in sialic acid 
biosynthesis are exceedingly rare (32). The five carbon of neuraminic acid is 
frequently modified with an N-acetyl group (Neu5Ac), which can be further 
hydroxylated to form N-glycolylneuraminic acid (Neu5Gc) (29). Additional 
modifications can involve acetylation, methylation, and sulfation of various 
hydroxyl groups. Sialic acid is often α-linked from the two carbon via different 
linkages to carbohydrate chains found on the nearby saccharides of 
glycoproteins and glycolipids. Glycoproteins are polypeptide moieties with 
glycans attached via the nitrogen atom of an asparagine side chain (N-linked) or 
the oxygen atom of a serine or threonine side chain (O-linked). Gangliosides are 
amphipathic glycosphingolipids containing a hydrophobic ceramide tail and a 
hydrophilic head with a sialylated carbohydrate moiety (33). Glycoproteins (34-
36) and gangliosides (35) can function as viral attachment factors. Virus 
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interactions with terminal sialic acid moieties of glycoproteins and gangliosides 
are usually of low affinity and strengthened by the multivalency of the virus.  
 
Viruses and gangliosides 
Gangliosides are divided into three main classes, the asialo-series, a-
series, and b-series (37). The gangliosides discussed further in this thesis are a-
series gangliosides. GM3, the simplest a-series ganglioside, is formed when 
GM3 synthase catalyzes the addition of an α2,3-linked sialic acid onto a lactose 
moiety with a ceramide tail. GM3 is the precursor of GM2 (Figure I-1), which is 
processed when GM2/GD2 synthase adds an N-acetylgalactosamine (GalNAc) 
to GM3. GM2 is the precursor for gangliosides GM1 and GD1a. Gangliosides are 
required for normal development as mice lacking GM3 and GM2 synthases die 
as embryos (38). Gangliosides also serve as receptors for several non-
enveloped viruses. For example, murine norovirus recognizes sialic acid on 
GD1a and GT1b, and GM1 is a receptor for human rotavirus strains KU, MO, 
DS-1, and Wa (39). Additionally, GD1a and GT1B are receptors for murine 
polyomavirus (mPyV) and simian virus 40 (SV40) recognizes GM1 (25).  
 
Studying sialic-acid virus interactions 
While viruses have been known for some time to use cell-surface sialic 
acid to initiate infection, recent advances in glycan microarray (glycan array) 
screening technology (40) have rapidly accelerated studies of carbohydrate-
binding ligands. Coupled with new structural information about how viruses bind 
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Figure I-1. A-series ganglioside biosynthesis pathway. Lactose-ceramide 
(Lac-cer) is comprised of a ceramide bound glucose (glc) linked to a galactose 
(gal) and servers as the precursor for ganglioside synthesis. GM3 synthase 
catalyzes the addition of an α2,3-linked sialic acid or neuraminic acid (Neu5Ac) to 
the galactose moiety. GM2 is generated when GM2 synthase catalyzes the 
addition of a N-acetylgalactosamine (GalNAc) to the GM3 precursor. This step is 
indicated with a blue arrow and box. GM2 can be further processed to form 
gangliosides GM1 and GD1a. Gangliosides GM3, GM2, and GM1 will be 
discussed further in this thesis with emphasis on GM2 and GM2 synthase. 
(Figure adapted from Furukawa et al. 2002 (37)).    
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 to sialylated glycans as well as the advent of reverse genetics (41, 42), virus-
glycan interactions can now be analyzed in unprecedented detail. Historically, a 
requirement for virus-sialic acid binding was investigated using cell-based assays 
in which viral infectivity was monitored following treatment with sialic acid-binding 
lectins or enzymatic removal of sialic acid using various types of neuraminidases. 
Certain biantennary glycans including ganglioside GM1, are resistant to 
neuraminidase treatment (43). Moreover, sensitivity is limited to the linkage-basis 
of the sialic acid moiety. Glycan array screening allows finer differences in virus-
glycan binding preferences to be discerned and augments the classical approach 
by enabling rapid, high-throughput screening of numerous glycans as potential 
virus receptors (40, 44-46). This technology has been used to identify 
carbohydrate ligands of adenovirus (36), influenza virus (47, 48), polyomavirus 
(49), rotavirus (22, 23), and reovirus (10), among others. Glycan array screening 
also has been highly valuable in identifying glycan specificity differences among 
related virus strains (47, 50, 51). 
 
Viruses that engage sialylated receptors 
Influenza virus-sialic acid interactions are well-studied. The 
hemagglutinin protein (HA) of influenza virus binds sialic acid to adhere the virus 
to the cell-surface. Receptor-binding specificities strongly influence host range, 
with avian strains preferring α2,3-linked sialic acid and human strains preferring 
α2,6-linked sialic acid (26, 52). Glycan array studies have highlighted more 
distinct glycan-binding preferences for specific strains (53). Influenza virus 
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interacts with sialic acid at multiple points during its infectious cycle. Binding of 
HA to cell-surface sialic acid initiates infection, but the virus must remove sialic 
acid from the cell surface and its glycoproteins to allow viral release. This 
function is mediated by a virus-encoded neuraminidase (NA), which is an 
important target of antiviral therapy (54, 55). NA cleavage specificities are finely 
tuned to HA binding preferences to facilitate viral exit. Thus, the HA and NA 
proteins must function in concert for efficient replication and infection (56, 57).  
Certain adenovirus types bind to sialic acid. For example, the species D 
adenovirus 37 (Ad37) agglutinates human red blood cells (58) in a 
neuraminidase-sensitive manner (59, 60). These findings indicate a requirement 
for sialic acid binding by this adenovirus type. Glycan array screening 
demonstrated that Ad37 binds specifically to the GD1a glycan on O-linked 
glycoproteins (36). Soluble GD1a diminishes the capacity of Ad37 to bind and 
infect human corneal epithelial cells, suggesting that GD1a serves as a functional 
receptor for at least some adenoviruses.  
Polyomaviruses also engage cell-surface sialic acid for efficient infection. 
Glycan array screening identified LSTc, a linear pentasaccharide that contains an 
α2,6-linked sialic acid, as a glycan receptor for human JC polyomavirus (JCV) 
(49). GD1a and GT1b are receptors for mouse polyomavirus (mPyV) (25). 
Polyomavirus binding to glycans mediates attachment, but in the case of mPyV, 
GD1a also facilitates transport of the virus to the endoplasmic reticulum (ER) 
prior to nuclear delivery (35, 61). The GD1a glycan present on both gangliosides 
and glycoproteins can bind mPyV. However, the GD1a ganglioside and not a 
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glycoprotein is responsible for viral trafficking to the ER (35), highlighting an 
additional role for sialylated glycans in viral infection.  
Rotaviruses are nonenveloped double-stranded RNA viruses from the 
Reoviridae family. Rotavirus attachment is dependent on glycans and mediated 
by the trimeric outer-capsid protein, VP4 (62). Rotavirus infectivity is enhanced 
following proteolytic cleavage of the VP4 trimer into N-terminal VP8* and C-
terminal VP5* subunits. The VP8* subunit serves as the viral hemagglutinin and 
binds to glycans (63), while the VP5* subunit facilitates membrane penetration 
(64). Animal rotaviruses tend to engage terminal sialic acid-containing receptors 
(65-70) and display neuraminidase-sensitive infectivity. Some human rotaviruses, 
such as the Wa strain, bind ganglioside GM1 (71). Neuraminidase cannot 
remove sialic acid from glycans such as GM1 and, thus, these strains were 
incorrectly presumed not to engage sialylated glycans. Yet, not all rotavirus 
strains bind sialylated glycans. A combination of glycan array screening and 
crystallographic analysis of VP8* from the human sialidase-insensitive strain 
HAL1166, P[14] VP4 genotype, demonstrated that this virus specifically engages 
A-type histo blood group antigen (HBGA) (22). HBGAs are oligosaccharides 
expressed on erythrocytes and epithelial cells and also present in mucosal 
secretions.  
 
Perturbing virus-sialic acid interactions 
Virus-sialic acid interactions can be altered with surprisingly few 
mutations. For example, two amino acid changes in the 1918 HA receptor-
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binding site shift the binding preference of the virus from α2,6- to α2,3-linked 
sialic acid (47). The virus that binds α2,3-linked sialic acid retains virulence in 
ferrets but is incapable of droplet transmission, unlike the α2,6-linked sialic acid-
binding strain (72). A switch in avian H5N1 from α2,3-linked to α2,6-linked sialic 
acid allows spread in ferrets by direct contact but is not sufficient to allow droplet 
transmission (73). Therefore, further adaptations are required to potentiate 
pandemic spread.  
GM1 serves as a functional receptor for polyomavirus SV40 (25). An 
SV40-GM1 escape mutant containing only three amino acid changes from 
wildtype virus binds to cells less efficiently and is not neutralized by soluble GM1. 
This mutant displays enhanced capacity to infect cells with low GM1 expression, 
likely the result of binding to another ganglioside (74). B series gangliosides 
GD3, GD2, GD1b, and GT1b share a common α2,8-linked motif and function as 
receptors for human BK polyomavirus (BKPyV) (51). Structure-guided 
mutagenesis studies using the crystal structures of BKPyV in complex with GD3 
and SV40 in complex with GM1 demonstrated that a single amino acid 
substitution in BKPyV switches receptor specificity in cell culture to that of GM1 
(51). These findings provide a framework for targeting viruses to new receptors.  
 
Virus-glycan engagement influences host range and pathogenesis 
Zoonotic transmission of viruses often results from alterations in receptor 
specificity. The binding preference of human influenza virus strains for α2,6-
linked sialic acid and avian strains for α2,3- linked sialic acid (48, 52) mirrors the 
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pattern of sialic acid expression of the target host as defined by lectin-based 
immunohistochemistry. In humans, α2,6-linked sialic acid is expressed on ciliated 
tracheal epithelial cells (75) and epithelial cells in the sinuses, pharynx, and 
bronchioles (76). Nonciliated cells of the lower respiratory tract express α2,3-
linked sialic acid (75, 76). In birds, α2,3-linked sialic acid is the dominant form in 
the respiratory and intestinal tracts. The switch in receptor specificity from avian 
α2,3-linked to human α2,6-linked sialic acid is a major factor in the emergence of 
pandemic influenza viruses. The 1918 H1N1, 1957 H2N2, 1968 H3N2, and 2009 
H1N1 strains were not of human origin but acquired human α2,6-linked sialic acid 
receptor-binding specificity (47, 77-79). In contrast, highly pathogenic avian 
H5N1 influenza virus strains have a strict requirement for α2,3-linked sialic acid 
and consequentially spread inefficiently from birds to humans. However, the virus 
can replicate in the lower respiratory tract of humans where α2,3-linked sialic 
acid is expressed. Therefore, H5N1 strains are virulent in humans. These 
observations also indicate that sialic acid-binding influences influenza virus 
tropism within the host (80).  
Mutations that shift influenza virus binding specificity from avian to human 
receptors are not always conserved among HA types. Mutations that shift H1 HA 
from α2,3- to α2,6-linked sialic acid do not result in α2,6-linked sialic acid binding 
by the H5 HA. These mutations only alter the affinity of H5 HA for α2,3-linked 
sialic acid. In contrast, mutations that convert H3 viruses from avian to human 
receptor specificity allow H5N1 binding to α2,6-linked sialic acid (81).  
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In addition to linkage variations, sialic acid modifications also can 
influence infectivity. The HA protein of human H3 viruses binds Neu5Ac and 
does not replicate in the duck intestine. However, the addition of two mutations 
confers binding to Neu5Gc and permits replication in ducks. Neu5Gc is 
expressed in areas targeted by the mutant virus, suggesting that recognition of 
Neu5Gc is important for infection (82). While it is certainly well studied, the 
intimate relationship between sialic acid and viral disease is not unique to 
influenza virus.  
Polyomavirus tropism also is affected by virus-sialic acid interactions. 
Polyomaviruses transform cells in culture, but only some mPyV strains induce 
tumors in mice (83). Small-plaque-forming virus, RA, induces few tumors in mice, 
whereas the large-plaque-forming strain, PTA, is highly tumorigenic (84, 85). 
Residue 91 of the major capsid protein VP1, which is contained within the sialic 
acid-binding pocket, dictates this phenotype (86-89). Glycine at position 91, as 
seen in RA, accommodates straight-chain and branched sialyloligosaccharides, 
while glutamic acid at this position, as seen in PTA, does not accommodate 
branched sialyloligosaccharides (87-89). A G91E mutation in RA increases 
tumorogenicity in mice, while the reciprocal E91G mutation in PTA attenuates 
disease (90), thus providing an unambiguous link between a single amino acid 
substitution and disease severity. Attenuation of RA strains is thought to be a 
consequence of binding to branched sialyloligosaccharides that serve as 
pseudoreceptors and route the virus to non-productive entry pathways.  
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Human BKPyV binds GD3, whereas SV40 binds GM1. A mutation in 
BKPyV switches sialic acid-binding preference from GD3 to GM1. Moreover, the 
mutant displays species-specific tropism. BKPyV K68S is specific for GM1-
Neu5Ac, the common form of GM1 found in humans. Conversely, SV40 prefers 
GM1-Neu5Gc, the common form in apes (51). Preference for Neu5Gc in SV40 is 
achieved by a larger, more polar pocket that can accommodate the hydroxyl 
group of the glycolyl chain. These observations raise the possibility that 
polyomavirus species jumps are mediated by changes in sialic acid-binding 
specificity.  
Alterations in glycan-binding capacity influence rotavirus disease outcome. 
Silencing the expression of ganglioside synthesis genes using RNA interference 
decreases ganglioside production and diminishes the capacity of human, bovine, 
porcine, and simian rotaviruses to infect cells in vitro (91). Sialic acid binding also 
influences pathogenesis in mice. Administration of bovine submaxillary mucin, 
which contains sialic acid, prevents gastroenteritis and diminishes rotavirus 
shedding in these animals (92). Ovine erythrocytes, which are naturally covered 
with sialic acid, also block rotavirus replication (92). Concordantly, neuraminidase 
treatment of these red blood cells negates the therapeutic effect (92). Reoviruses 
also engage sialylated glycans, and these virus-carbohydrate interactions 
influence tropism in the host.  
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Reoviruses 
Reovirus background 
Reoviruses are nonenveloped viruses with icosahedral symmetry. Virions 
contain 10 segments of dsRNA that are divided into three classes based on size. 
The three large gene segments, L1, L2, and L3, encode proteins λ3, λ2, and λ1, 
respectively, which are approximately 140 kDa in size. The three medium 
segments, M1, M2, and M3, encode μ2, μ1, and μNS, respectively, which are 
about 80 kDa in size. The small segments are designated S1, S2, S3, and S4. 
S1 encodes both σ1, the viral attachment protein (93) and subject of this thesis, 
and σ1s, a nonstructural protein required for reovirus cell-cycle arrest (94, 95). It 
is noteworthy that all of the mutations engineered in the S1 gene in my studies 
are not within the σ1s reading frame and can be definitively associated with σ1. 
The S2, S3, and S4 gene segments encode σ2, σNS, and σ3, respectively. While 
σ1s is 14,000 kDa in size, all other proteins encoded by reovirus S genes are 
approximately 40-50 kDa. (Table I-1). These ten segments of dsRNA are 
encapsidated within two concentric protein shells, the outer capsid and inner 
core. The outer capsid is comprised of σ1, σ3, and μ1 (Figure I-2). Most children 
are seropositive for reovirus by five years of age (96). Reovirus causes mild 
respiratory illness or gastroenteritis. In rare cases, reovirus disseminates in 
newborn infants and causes central nervous system disease (97).  
Reoviruses have a broad host range in nature, infecting nearly all 
mammals. Reovirus is a tractable experimental system for studies of virus-
receptor interactions, viral cell entry, and viral pathogenesis because they  
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Table I-1. Reovirus gene segments and protein products. The reovirus gene 
segments and corresponding proteins are shown.  
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Figure I-2. The reovirus virion. Schematic of a reovirus virion (left). Reovirus 
particles are composed of two concentric protein shells, the outer capsid and 
inner core. The inner core contains the viral genome consisting of ten segments 
of double-stranded RNA. Cryo-electron micrograph image reconstruction of a 
reovirus virion (right). Outer capsid protein σ3 (blue) is removed during virion 
disassembly in infected cells. Pentameric λ2 protein (yellow) forms the base for 
insertion of the σ1 attachment protein (added in black). (Figure adapted from 
Nason et al. 2001 (98)).   
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produce high titer, facilitating biochemical and biophysical studies, and the virus 
and host can be manipulated genetically to define determinants of pathogenesis 
in each. 
 
A history of common laboratory strains 
There are three serotypes of reoviruses, designated as serotype 1, 2, and 
3 that are represented by prototype strains type 1 Lang (T1L), type 2 Jones 
(T2J), and type 3 Dearing (T3D). Prototype strain T1L was isolated in 1951 from 
a healthy child (99), while prototype strains T2J and T3D were isolated from the 
stools of children with diarrhea also in the early 1950s (99-101).  
 
Reovirus reverse genetics 
Classically, isolation of viral mutants incapable of binding receptors 
required propagating viruses in the presence of excess soluble receptor to select 
for escape mutants in a process termed forward genetics. For most viruses, 
including reovirus, it is now possible to rationalize mutations, sometimes using 
structural data, and generate single and multiple point mutants using a process 
termed reverse genetics. In the reovirus reverse genetics system (41, 42), 
cDNAs corresponding to each of the reovirus gene segments are encoded on 
plasmids, either alone or in combination. The cDNAs are flanked by the promoter 
sequence for T7 polymerase and the hepatitis delta virus (HDV) ribozyme. The 
plasmids are transfected into baby hamster kidney (BHK) cells that constitutively 
express T7 polymerase, thus driving transcription of the plasmid-encoded 
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reovirus genes. The HDV ribozyme cleaves the cDNA, ensuring that the 3’ ends 
of the transcripts are in their native form. 
Once inside cells, host ribosomes translate the mRNAs, yielding reovirus 
proteins. Replication complexes form and drive negative-strand RNA synthesis. 
Infectious virions form and, following a few replication cycles, the BHK-T7 cells 
are frozen and thawed to release all reovirus virions. Supernatants are then used 
to infect L cells and generate reovirus stocks (41, 42). Site-directed mutagenesis 
can be used to generate plasmids encoding mutant viral cDNAs, thereby 
enabling directed engineering of mutant viruses.  
 
Reovirus tropism 
After peroral inoculation, reovirus infects M cells on the surface of Peyer’s 
patches in the intestine (102, 103) and disseminates to sites of secondary 
replication including the heart, liver, and brain (104). Reovirus displays serotype-
dependent pathology in the central nervous system (CNS) of newborn mice, 
which are highly susceptible to infection and disease. 
T1 reovirus, the subject of this thesis, spreads via hematogenous routes, 
infects ependymal cells that line the brain ventricles, and causes hydrocephalus 
(16, 105-107). Disease begins with acute ependymitis, followed by 
hydrocephalus (16, 108). Affected mice display dilation of the lateral and third 
ventciles, with some animals developing intraventricular hemorrhage. 
Compression of the midbrain leads to aqueductal stenosis. The majority of the 
reovirus-infected foci are ependymal cells, but occasional neuronal necrosis 
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occurs at limited sites (106). Ependymal cells succumb to necrosis, and the 
ependymal layer is denuded over the course of infection (16, 108). Inflammatory 
infiltrate and debris subsequently block the aqueduct (106). Both the ependymal 
cells and choroid plexus are irregular and vary in cellular density. In some cases, 
tissue grows into the ventricular cavities, resulting in obstruction (108). Reovirus 
titers are often below the level of detection by the time of disease onset (107). 
Thus, reovirus-induced obstructive hydrocephalus is a consequence of damage 
to the ependyma and chorid plexus.  
Conversely, T3 reovirus disseminates via neural and hematogenous 
routes (12, 104, 109), infects CNS neurons, and causes lethal encephalitis (17, 
110-112). Encephalitis is associated with neuronal apoptosis and an influx of 
inflammatory cells (111, 113). While damage is observed in the neurons directly, 
T3 antigen is not detected in the ependymal cells (17, 114).  
 
Age restriction and immunity 
Reovirus displays age-dependent pathology. Mice 8 days of age and 
younger die following infection with T3 reovirus, while mice 10 days of age and 
older survive (115) (Wu and Dermody, unpublished observations). Mice 
inoculated between 10 and 21 days of life display less severe patchy encephalitis 
in comparison to those inoculated on or before the eighth day of life (115). 
Intracranial inoculation with T1L results in lower titers in the brains of older 
animals relative to their younger counterparts (115). Mechanisms by which 
reovirus disease is restricted to the very young are not well understood. 
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However, it is possible that differences in receptor expression, immune system 
function, or both contribute to this phenomenon.  
Immune system function contributes to protection against viral disease. 
Transfer of reovirus-immune adult splenocytes protects neonatal mice from T1-
induced hydrocephalus. This protection is diminished if either CD4+ or CD8+ T 
cells are depleted. While reovirus-immune cells protect neonatal mice from T3D-
induced encephalitis following intramuscular inoculation, these cells do not 
protect neonatal mice from T3D-induced encephalitis resulting from direct 
intracranial inoculation (116). T3-specific antibody 9BG5 decreases viral spread 
within the CNS but does not influence reovirus titers at sites of primary infection 
(117, 118). The addition of functional T cells and immunoglobulin benefits the 
host, and alternatively, the absence of these functional cells in otherwise healthy 
animals worsens disease. Adult severe combined immunodeficiency (SCID) 
mice, which lack functional Peyer’s patches, B cells, and T cells, succumb to a 
lethal hepatitis. Transfer of reovirus-immune Peyer’s patch cells can protect 
these animals (119). Taken together, these findings suggest that the developed 
immune system in adult mice contributes to resistance against reovirus-mediated 
disease.  
 
Contribution of the S1 gene to serotype-specific disease 
The viral S1 gene, which encodes σ1 and σ1s, determines serotype-
dependent differences in CNS disease (17, 104, 110, 120), likely through 
differential engagement of cell-surface receptors. This phenomenon was 
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demonstrated using reassortant reoviruses 3HA1, comprised of 9 segments of 
strain T3D and a T1L S1 gene, and the reciprocal 1HA3 reassortant, containing a 
T3D S1 gene in an otherwise T1L genetic background. T1L and 3HA1 cause 
hydrocephalus but not encephalitis in mice, whereas T3D and 1HA3 result in a 
lethal encephalitis but not hydrocephalus (17, 114). T1L and 3HA1 bind to 
ependymal cells, while T3D reovirus and 1HA3 do not. T1L binds similarly to 
adult and neonatal ependymal cells (105), suggesting that age-mediated disease 
is not a consequence of altered receptor expression, at least by ependymal cells.  
 
Reovirus attachment protein σ1 
The σ1 protein, encoded by the S1 gene, serves as the reovirus 
attachment protein for all serotypes. It is a long, filamentous trimer that extends 
from the λ2 protein at the five-fold vertices of the virion icosahedron (121-123). 
The σ1 protein is partitioned into three structurally-distinct domains, an N-
terminal α-helical coiled-coil tail, a central body formed from a triple β-spiral, and 
a C-terminal eight-stranded β-barrel head (9, 123, 124) (Figure I-3). The N-
terminal tail inserts into the virion and the head projects away from the virion 
surface (121).  
 
Reovirus receptors 
T1 and T3 reovirus use immunoglobulin superfamily member JAM-A as a 
receptor (11, 125). JAM-A is expressed at tight junctions in polarized cells and on 
some leukocytes (126-129). The head domain of both T1 and T3 σ1 proteins 
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binds to JAM-A with high affinity using virtually identical binding surfaces (130) 
(Kirchner-Stettner and Stehle, unpublished) (Figure I-3). Studies using JAM-A-
null mice indicate that JAM-A promotes hematogenous spread of reovirus (12). 
Expression of JAM-A in endothelial cells is required for hematogenous spread, 
while hematopoietic JAM-A is dispensable (Lai and Dermody, unpublished). 
JAM-A is not required for reovirus infection of the murine intestine and brain (12) 
and likely does not contribute to serotype-specific disease.  
 A second proteinaceous receptor for reovirus, NgR1, was identified using 
a genome-wide siRNA screen (15). This leucine rich-repeat protein (131-134) 
regulates axonal pasticity during development and prevents axonal regeneration 
in adults (135, 136). The NgR1 binding site on the reovirus virion has not been 
defined. However, reovirus virions, but not infectious subvirion particles (ISVPs), 
an assembly intermediate displaying an altered conformer of σ1 and loss of σ3, 
bind NgR1. This observation suggests that NgR1 binds a conformation-specific 
form of σ1, outer-capsid protein σ3, or perhaps both (15). The effect of NgR1 
engagement on disease is not known. NgR1 mediates T3 reovirus infection of 
neurons in vitro (15); however, overexpression of NGR1 in CHO cells also 
permits T1L to infect these otherwise non-susceptible cells. Thus, the function of 
NgR1 in serotype-specificity is not clear but is an area of active exploration 
(Konopka-Anstadt and Dermody, unpublished). 
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Figure I-3. Model of reovirus σ1 attachment protein. The σ1 attachment 
protein is depicted with experimentally determined structures shown in blue, red, 
and yellow, indicating the individual monomers comprising the trimeric protein; 
modeled regions are shown in gray. The tail, body, and head domains are 
indicated. The T1 and T3 JAM-A- binding site and T3 sialic-acid-binding site are 
indicated. Structures of these virus-receptor interactions are shown as insets. 
(Figure adapted from Chappell et al. 2002 (123), Reiter et al. 2011 (9), Reiss et 
al. 2012 (10), and Dietrich and Stehle, unpublished). 
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Serotype-dependent glycan binding by reovirus 
Reoviruses were first appreciated to bind glycans through 
hemagglutination experiments conducted more than 50 years ago (137). 
Hemagglutination is a carbohydrate-dependent process, as treatment with 
sodium periodate diminishes hemagglutination capacity (137). T1 reovirus 
agglutinates erythrocytes of human and non-human primates, whereas T3 
reovirus agglutinates erythrocytes from a variety of mammalian species. 
Interestingly, T1 reovirus agglutinates human erythrocytes more efficiently than 
does T3 reovirus. T3 binds to glycophorin on erythrocytes, whereas T1 reovirus 
does not (138). TheT3 σ1 sialic acid binding site is in the body domain (8, 9), 
while the T1 σ1 carbohydrate-binding site was thought to be beneath the head 
domain, as assessed by hemagglutination studies using chimeric σ1 molecules 
(8). Such differences in hemagglutination behavior suggest that T1 and T3 
reovirus bind distinct glycans.  
While the precise carbohydrate ligands of T3 reovirus σ1 are not known, 
the T3 σ1-sialic acid interaction is well characterized. T3 σ1 binds α2,3-, α2,6-, 
and α2,8-linked Neu5Ac using the loop connecting β-spirals two and three in the 
body domain(9). A bidentate salt bridge between the sialic acid carboxylate and 
Arg202 of T3 σ1 forms a key interaction between virus and glycan. This salt 
bridge is required for the interaction, as an arginine to tryptophan substitution at 
residue 202 abolishes sialic acid-binding capacity (9). Additionally, hydrogen 
bonds between the hydroxyl, acetyl, and glycerol groups of sialic acid and the 
backbone carbonyl groups of T3 σ1 strengthen the interaction.  
24 
 
Glycan binding capacity alters T3 reovirus disease. Binding of T3 reovirus 
to sialic acid enhances dissemination from the intestine to sites of secondary 
replication including the brain, heart, and liver. T3 reoviruses differing only in the 
capacity to engage sialic acid display marked differences in tissue tropism in 
mice (139). Strain T3SA+ binds sialic acid, whereas T3SA- differs by a single 
residue in σ1 and cannot engage this carbohydrate (139). T3SA+ infects and 
injures the bile duct epithelium, resulting in an oily hair syndrome, whereas 
isogenic strain T3SA- does not induce this damage (139). T3D binds sialylated 
glycans and replicates to higher titers in the murine spinal cord and brain 
compared with a mutant containing an arginine-to-tryptophan substitution at 
residue 202 in the σ1 body domain (140). While neuraminidase treatment had 
been shown to reduce T1L binding to rabbit Peyer’s patch explants (141), the 
importance of glycan engagement in T1 reovirus pathogenesis had not been 
investigated prior to my thesis work. 
  
Hypothesis 
Given that reoviruses disseminate with serotype-specific tropism, engage 
the same known proteinaceous receptors, yet interact with distinct glycans, I 
hypothesized that T1 reovirus engages host cell glycans and that this binding 
influences tropism in the murine host.  
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Significance 
Receptor utilization has broad implications for viral disease, often 
influencing host range and pathogenesis. The reovirus reverse genetics system 
and mouse model of disease make it a useful model to manipulate both the host 
and pathogen to elucidate mechanisms of viral attachment and evaluate the 
effects of receptor engagement on disease. This work sheds light on more 
general principles of virus-glycan interactions and the function of receptor 
engagement in tropism and pathogenesis. Furthermore, reovirus is being 
developed as a vaccine vector and oncolytic agent (142-144). Cancer cells 
display altered glycan profiles (145). Thus, understanding reovirus-glycan 
interactions may enhance design of reovirus vectors for therapeutic applications. 
  
26 
 
CHAPTER II 
 
IDENTIFICATION OF A CARBOHYDRATE BOUND BY SEROTYPE 1 
REOVIRUS σ1 
 
Introduction 
Reoviruses engage cell-surface carbohydrates as first demonstrated in 
hemagglutination studies (137). The molecular and biophysical basis of T3 
reovirus-sialic acid binding as well as the function of sialic acid engagement in 
disease were well established prior to my thesis research (7-9, 24, 139, 140, 
146). However, before beginning this project, the interaction of T1 reovirus with 
cell-surface carbohydrates was not understood. Differences in hemagglutination 
behavior between T1 and T3 reoviruses suggested that these serotypes 
differentially interact with cell-surface carbohydrates. Additionally, one study 
showed that neuraminidase treatment to remove cell-surface sialic acid 
diminishes the capacity of strain T1L to infect M cells on Peyer’s patch explants 
(141). Taken together, these observations suggest that T1 reovirus engages 
different sialylated glycans than does T3 reovirus. However, specific host glycans 
bound by any mammalian reovirus had not been defined. I sought to identify a 
specific glycan bound by T1 reovirus. The establishment of a precise 
carbohydrate that interacts with T1 reovirus would facilitate studies of the 
biophysical basis of σ1-glycan interactions and enhance studies to evaluate the 
function of glycan binding in pathogenesis. Moreover, understanding how 
27 
 
reoviruses interact with cell-surface glycans could improve their efficacy as 
oncolytic therapeutics. 
I worked with Kerstin Reiss in the laboratory of Dr. Thilo Stehle at the 
University of Tübingen, Germany and Yan Liu in the laboratory of Dr. Ten Feizi, 
Imperial College of London, United Kingdom to identify a specific glycan bound 
by T1 reovirus. Data presented in this chapter reflect that collaboration. Kerstin 
Reiss generated the σ1 protein used in the glycan array that was performed by 
Yan Liu shown in Figure II-5. I designed and conducted all infectivity and binding 
experiments shown in the other figures.  
 
Results 
Establishing a cell-culture system 
T3 reovirus-sialic acid interactions were investigated using murine 
erythroleukemia (MEL) cells, which are susceptible only to sialic-acid binding 
strains of T3 reovirus, and L929 (L) cells, which are permissive to sialic acid-
binding and non-binding strains (7, 9, 139, 147). MEL cells are not susceptible to 
infection by T1 reovirus. Therefore, studies of T1 σ1-glycan interactions were 
hindered by the lack of a suitable cell-culture system. To establish an in vitro 
setup in which glycans bound by reovirus could be identified and residues in T1 
σ1 required for functional carbohydrate engagement could be discerned, I tested 
HeLa cells, L cells, and murine embryonic fibroblasts (MEFs) for the capacity to 
support reovirus infection in the presence and absence of A. ureafaciens 
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neuraminidase, a broad spectrum sialidase that cleaves α2,3-, α2,6-, α2,8-, and 
α2,9-linked sialic acid from the cell surface (148). As expected, neuraminidase 
treatment of L cells did not alter T1L infectivity (Figure II-1A) but diminished the 
capacity of T1L to infect both MEFs (Figure II-1B) and HeLa cells (Figure II-1C). 
This finding indicates that sialylated glycan engagement is required for optimal 
T1 reovirus infectivity in some cell types. Moving forward, I used L cells and 
MEFs as murine cell types that display glycan independent and dependent 
infectivity, respectively.  
The disparity displayed by L cells and MEFs in the dependence of T1 
reovirus infectivity on sialic acid binding is likely a consequence of differences in 
expression of proteinaceous receptor JAM-A. L cells, which are susceptible to T1 
reovirus infection in the absence of sialic acid engagement, express higher levels 
of cell-surface JAM-A than do MEFs, which are most susceptible to sialic-acid 
binding strains (Figure II-2). T1L may infect MEFs using an adhesion 
strengthening mechanism, similar to that used by T3 reovirus to infect cells (7), in 
which binding to glycan precedes binding to the relatively low abundance JAM-A 
receptor.  
Lectin-based glycan identification 
Experiments using neuraminidase indicate that a sialic-acid-bearing 
glycan is required for optimal reovirus infectivity of MEFs. One previous study 
demonstrated that the plant lectin, Maackia amurensis lectin (MAL-II), which 
binds α2,3-linked sialic acid, blocks the capacity of T1L ISVPs to adhere to M  
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Figure II-1. The effect of neuraminidase treatment on T1L infectivity in 
various cell types. (A) L cells, (B) MEFs, or (C) HeLa cells were treated with A. 
ureafaciens neuraminidase for 1 h, followed by adsorption of T1L at MOIs of 10, 
100, or 100 PFU/cell, respectively. Cells were washed twice with PBS, and fresh 
medium was added. After incubation at 37°C for 20 h, cells were fixed, and 
reovirus antigen was detected by indirect immunofluorescence. Nuclei were 
stained with DAPI. The percentage of infected cells in three fields of view per well 
was determined. The results are expressed as the mean percent infected cells 
per well in triplicate wells for two independent experiments. Error bars represent 
standard deviations. ***, P < 0.001, as determined by two-tailed Student’s t test.  
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Figure II-2. JAM-A expression on L cells and MEFs. L cells or MEFs were 
stained with anti-JAM-A antibody followed by Alexa-488 labeled secondary 
antibody to assess cell-surface JAM-A expression. Fluorescence was detected 
by flow cytometry. Cells were gated on forward and side scatter, and the mean 
fluorescence intensity (MFI) of Alexa-488 was quantified. Results shown are from 
a representative experiment of three performed in duplicate.  
31 
 
cells on rabbit Peyer’s patch explants (141). To determine the linkage-specificity 
of the sialylated glycan bound by T1 reovirus on the MEF cell surface, I tested 
the capacity of plant lectins to block T1L infectivity of MEFs. I employed α2,3-
linked-sialic-acid-specific MAL-II and Sambucus nigra lectin (SNA), which binds 
α2,6-linked sialic acid and α2,3-linked sialic acid to a lesser degree. Aleuria 
aurantia lectin (AAL) binds α1,2-linked fucose and was used as a control. 
Incubation of MEFs with MAL-II or SNA decreased the infectivity of T1L relative 
to vehicle control, while AAL did not have an effect (Figure II-3). The lectins that 
blocked T1L infectivity of MEFs both interact with α2,3-linked sialic acids, 
suggesting that T1 reovirus interacts with α2,3-linked sialic-acid-bearing-glycans.  
To complement this approach, I assessed the capacity of soluble 3’ 
sialyllactose (3’ SL), a simple molecule comprising a glucose bound to a 
galactose with an α2,3-linked sialic acid, to diminish T1 reovirus infectivity. 
Incubation of T1L with high doses of 3’SL had no effect on infectivity of MEFs 
(Figure II-4), suggesting that another glycan with an α2,3-linked sialic acid and 
not 3’SL is the functional receptor for T1 reovirus. Therefore, we needed to test a 
broader panel of candidate glycans to identify a functional binding partner for T1 
σ1.  
Glycan array screening 
We used glycan array screening in collaboration with the Feizi and Stehle 
laboratories to identify precise glycans bound by T1 reovirus σ1. Two 
independent neoglycolipid arrays were used in this study. Sialylated glycans and  
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Figure II-3. The effect of soluble lectins on T1L infectivity in MEFs. T1L was 
pre-incubated with the lectins shown at a concentration of 10 μg/ml for 1 h prior 
to adsorption to MEFs at an MOI of 100 PFU/cell. Cells were washed twice with 
PBS, and fresh medium added. After incubation at 37oC for 20 h, cells were 
fixed, and reovirus antigen was detected by indirect immunofluorescence. Nuclei 
were quantified by DAPI staining. The percent of infected cells in three fields of 
view per well was quantified.  Results shown are from a representative 
experiment of 2 performed in triplicate wells. Error bars represent standard 
deviations. *** , P < 0.001, as determined by one-way ANOVA followed by a 
Bonferroni multiple-comparison post-test.  
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Figure II-4. The effect of soluble 3’ sialyllactose on T1L infectivity in MEFs. 
T1L was incubated with 5 mM 3’ sialyllactose for 1 h prior to adsorption to MEFs 
at an MOI of 100 PFU/cell. Cells were washed twice with PBS, and fresh medium 
was added. After incubation at 37oC for 20 h, cells were fixed, and reovirus 
antigen was detected by indirect immunofluorescence. Nuclei were quantified by 
DAPI staining. The percent of infected cells in three fields of view per well was 
quantified.  Results shown are from a representative experiment of two 
performed in triplicate wells. Error bars represent standard deviations. 
Differences are not significant as determined by two-tailed Student’s t test.  
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non-sialylated control glycans were attached via lipid anchors to nitrocellulose 
membranes. His-tagged σ1 was adsorbed to these plates, and binding of σ1 to 
glycans was detected by immunofluorescence. Experiments using these arrays 
identified the GM2 glycan as a potential carbohydrate bound by T1 σ1. Related 
a-series gangliosides, GM3, GM1, and GD1a, yielded marginally detectable 
signals on the second glycan array performed for T1 σ1 (Figure II-5). Of note, T3 
σ1 did not bind to GM2 on glycan arrays done in parallel (Liu and Feizi, 
unpublished). The GM2 glycan contains two terminal sugar moieties, an N-
acetylgalactosamine (GalNAc) and a neuraminic acid (Neu5Ac), which are both 
bound to a central galactose via β1,4 and α2,3 linkages, respectively. This 
galactose is connected through a β1,4 linkage to a glucose molecule. In the full 
ganglioside, the glucose is connected to a ceramide tail that anchors the 
ganglioside in the lipid membrane. In the glycan form, only the sugar moieties, 
and not the ceramide, are present. Binding of T1 σ1 protein to the GM2 glycan 
was confirmed using NMR spectroscopy, which demonstrated that the Neu5Ac 
and GalNAc moieties interact with T1 σ1 in solution (10). I chose to use the GM2 
glycan as opposed to the ganglioside for published experiments as the same 
glycan preparations were employed by our collaborators in the Stehle lab for 
crystallography studies. Moreover, the glycan is soluble in PBS, which is used as 
a common vehicle for reovirus infection experiments, whereas the ganglioside 
must be suspended in DMSO, which can be toxic at higher doses. Thus, use of 
the glycan allowed me to work with a larger range of concentrations. 
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Figure II-5. Glycan array identification of GM2 as a candidate receptor. 
Glycan microarray analysis of recombinant T1L σ1 using 21 lipid-linked 
oligosaccharide probes. Each oligosaccharide probe was arrayed at four 
concentrations (as indicated) in duplicate. Numerical scores of the binding 
signals are means of duplicate spots (with error bars). A second array comprised 
of 124 lipid-linked oligosaccharide probes identified solely the GM2 glycan but 
had a higher signal-noise ratio.  
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Functional analysis of glycan array results 
To determine whether GM2 is a functional receptor for T1 reovirus, I 
tested soluble GM2 for the capacity to inhibit infection of MEFs. Incubation of T1L 
with GM2 glycan diminished the infectivity of T1L in a dose-dependent manner 
(Figure II-6A). Related glycan GM3 blocked infectivity to a lesser degree and not 
in a dose-dependent fashion (Figure II-6B). To evaluate the serotype-specificity 
of GM2 as a reovirus receptor, I incubated T3D with soluble GM2 and quantified 
infectivity. Interestingly, soluble GM2 had no effect on the capacity of T3 reovirus 
to infect MEFs (Figure II-6C), suggesting that reovirus binding to this glycan is 
serotype-specific.  
To establish whether soluble GM2 diminished T1L infectivity in MEFs due 
to a block in attachment, T1L was preincubated with soluble GM2, GM3, or GM1 
glycans or the PBS vehicle control prior to adsorption at 4°C to prevent 
internalization. Binding was assessed using flow cytometry. The GM2 glycan 
decreased the capacity of T1L to adhere to MEFs, GM3 inhibited binding to a 
lesser degree, and GM1 had no effect (Figure II-7), suggesting that T1 reovirus 
directly binds to glycans on the cell surface.  
 
Discussion 
Prior to the initiation of these studies, hemagglutination experiments 
demonstrated that the reovirus-mediated agglutination of erythrocytes is  
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Figure II-6. The effect of soluble glycans on T1L infectivity in MEFs. (A,B) 
T1L or (C) T3D (107 PFU/well) was incubated with the GM2 (A,C) or GM3 (B) 
glycans at the concentrations shown for 1 h prior to adsorption to MEFs at an 
MOI of 100 PFU/cell. Cells were washed twice with PBS, and fresh medium was 
added. After incubation at 37oC for 20 h, cells were fixed, and reovirus antigen 
was detected by indirect immunofluorescence. Nuclei were quantified by DAPI 
staining. The results are expressed as the mean percent infected cells per field in 
triplicate wells for two independent experiments. Error bars represent standard 
deviations. ***, P < 0.001, as determined by one-way ANOVA followed by a 
Bonferroni multiple-comparison post-test.  
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Figure II-7. The effect of soluble glycans on T1L attachment to MEFs. T1L 
virions were incubated with 2 mM of GM1, GM2, or GM3 at room temperature for 
1 h prior to adsorption to MEFs at an MOI of 2 x 105 particles/cell. After 
incubation at 4oC for 1 h, cells were washed twice with PBS, and binding was 
assessed by flow cytometry. The results shown are from a representative 
experiment of two performed in duplicate. **, P < 0.01, as determined by one-way 
ANOVA followed by a Bonferroni multiple-comparison post-test.  
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carbohydrate-dependent (137). Moreover, reovirus displays serotype-dependent 
hemagglutination profiles, suggesting that T1 and T3 reoviruses bind distinct 
glycans (8). T3 reovirus was known to bind α2,3-, α2,6-, and α2,8-linked sialic 
acid (9). However, lectins recognizing α2,3-linked sialic acid were shown to block 
T1L attachment to Peyer’s patch explants (141), indicating that T1 also may 
engage carbohydrates containing α2,3-linked sialic acid.  
Studies of virus-sialic acid interactions are slowly revealing that the 
interaction between a virus and a sialylated receptor may be more complex than 
the linkage-basis of the sialic acid alone. For example, human influenza viruses 
have long been appreciated to preferentially engage α2,6-linked sialic acid. One 
glycan array study investigating sialylated receptor binding by seasonal H3N2 
influenza virus strains that circulated between 1968 and 2012 demonstrated that 
there was variation in the binding preferences on an annual basis. Of note, there 
was not a single sialylated carbohydrate present on the array that bound every 
yearly strain (53). These findings indicate that linkage-specificity is not the sole 
determinant of virus-sialic acid engagement.  
In the experiments described in this chapter, glycan array screening 
identified the GM2 glycan as a candidate receptor for reovirus (Figure II-5). GM2 
contains an α2,3-linked sialic acid; therefore, this finding is in line with additional 
observations that sialic acid binding is required for optimal T1L infectivity in MEFs 
(Figure II-1) and that lectins recognizing α2,3-linked sialic acid inhibit reovirus 
infection in MEFs (Figure II-3). Soluble GM2 inhibited the capacity of T1 to infect 
MEFs (Figure II-6A). However, the GM3 glycan (Figure II-6B), also known as 
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3’SL (Figure II-4), does not block T1L infectivity of MEFs. While T3 reovirus was 
known to interact with α2,3-linked sialic acid, specifically, 3’SL or the GM3 glycan 
(9), soluble GM2 did not diminish T3 infectivity of MEFs (Figure II-6C). Moreover, 
parallel glycan array screening revealed that T3 reovirus σ1 interacted with a-
series gangliosides GM3, GM1, and GD1a, but no binding was detected to GM2 
(Reiter, Stehle, Liu, and Feizi, unpublished observations). Taken together, these 
experiments demonstrate that the GM2 glycan is a biologically relevant entry 
mediator for T1 but not T3 reovirus in MEFs. 
T1L attachment to cells was inhibited by the GM2 glycan (Figure II-7), 
suggesting that the block to infectivity results from diminished binding of the virus 
to the cell-surface. While the GM1 glycan had no effect on attachment, soluble 
GM3 diminished binding, albeit to a lesser degree than did GM2. The GM3 
glycan serves as the precursor for GM2 and lacks the GalNAc moiety on that 
glycan but is otherwise identical. As GM2 blocks binding and infectivity, while 
GM3 diminishes binding only, we thought it likely that the T1 σ1 protein interacts 
with sialic acid and the GalNAc moiety to enhance specificity. This hypothesis 
was confirmed in structural studies presented in Chapter 3.  
Reovirus is being evaluated in clinical trials as an oncolytic adjunct to 
conventional cancer therapy. Ganglioside expression, including GM2, is altered 
in many cancer cells compared with their untransformed counterparts (149) . 
Moreover, humanized anti-GM2 antibodies protect mice with small-cell lung 
cancer from metastases (150). It is possible that ganglioside overexpression in 
cancer cells alters susceptibility to reovirus infection. Thus, understanding the 
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precise ligands bound by reovirus could improve oncolytic vector targeting to 
certain tumors. 
  
42 
 
CHAPTER III 
 
DEFINING RESIDUES REQUIRED FOR FUNCTIONAL T1 σ1-GM2 BINDING 
 
Introduction 
The identification of residues required for viral receptor binding enhances 
an understanding of the molecular basis of the virus-glycan interaction and 
facilitates in vivo studies to investigate the function of receptor-engagement in 
viral pathogenesis. While residues in the body domain of T3 reovirus σ1 required 
for sialic acid binding had been defined (8, 9, 24), sequences required for T1 σ1-
glycan interactions were not known. Studies using reovirus σ1 protein expressed 
in insect cells using baculovirus vectors defined a region in the neck domain 
required for agglutination of human red blood cells. Additionally, purified T1 σ1 
constructs lacking the head domain also are incapable of hemagglutination (8). 
These findings suggest that residues in the head and neck regions of T1 σ1 are 
required for glycan binding.  
Several approaches can be used to successfully identify residues required 
for receptor binding, including alanine scanning mutagenesis, sequencing of field 
isolates differing in receptor engagement, and structure-guided mutagenesis. 
Investigators studying T3 reovirus-sialic-acid interactions capitalized on the 
existence of clinical isolates that differ in the requirement for sialic acid utilization 
to infect cells. T3 strains that do not bind sialic acid were serially passaged in 
MEL cells, which are susceptible to infection only by sialic-acid-binding T3 
reovirus strains. Sequencing the resultant MEL cell-adapted strains revealed that 
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specific residues within the T3 σ1 body domain are required for functional glycan 
engagement (7, 24). The importance of these residues in T3 σ1-sialic acid 
binding was confirmed using crystallography and site-directed mutagenesis (9).  
Advances in crystallography along with results from glycan array 
screening catalyzed studies conducted in parallel in the Stehle laboratory to 
determine the structure of T1 σ1 in complex with GM2. The success of the 
structural work, coupled with development of reverse genetics for reovirus (41, 
42, 151), made structure-guided mutagenesis the most efficient approach for me 
to use to define residues in T1 σ1 required for functional GM2 binding. I sought to 
engineer mutant viruses that might be altered in engagement of the GM2 glycan. 
The finding that T1L requires interactions with sialylated glycans to efficiently 
infect MEFs but not L cells (Figure II-1) provided a cell-culture system in which I 
could evaluate T1 σ1-glycan engagement. I set out to engineer mutant viruses 
that displayed impaired hemagglutination capacity and infectivity in MEFs relative 
to T1L but infected L cells comparably to wildtype virus. Mutant viruses showing 
defects in replication assays using L cells would suggest alterations in overall 
viral fitness, most likely as a consequence of mutation-induced gross misfolding 
of the σ1 protein. Viruses capable of infecting L cells, yet impaired in GM2 
engagement, would yield the most interpretable results in vitro and later in vivo.  
To understand the molecular basis of T1 reovirus σ1-glycan interactions, I 
collaborated with graduate student Kerstin Reiss who was completing her Ph.D. 
training with Thilo Stehle at the University of Tübingen, Germany. Kerstin was 
interested in the structural basis of reovirus-receptor interactions. She generated 
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the crystallography figures shown in this chapter (Figures III-1-4). Together, 
Kerstin and I rationalized the structure-guided mutant design (Tables III-1 and III-
2). Bärbel Blaum, a postdoctoral fellow in the Stehle laboratory, generated the 
NMR data shown in Figure III-13 after we collaboratively planned the experiment. 
I rescued the viruses using reverse genetics, generated virus stocks, and 
designed and conducted the infectivity, binding, and hemagglutination 
experiments shown in the other figures.  
 
Results 
Structure of the T1 σ1-GM2 complex 
Recombinant hexahistidine-tagged T1L σ1 protein constructs were 
expressed in E. coli and purified for use in X-ray crystallography studies to 
identify the T1 σ1 glycan-binding site. Two constructs, σ1long and σ1short, were 
designed using sequence alignment with T3D σ1, for which several crystal 
structures exist (9, 123, 152, 153). The first construct, σ1long, comprised amino 
acids 261-470, which were predicted to fold into three β-spiral repeats and the C-
terminal head domain. The second construct, σ1short, comprised amino acids 300-
470, which were predicted to form only the most C-terminal β-spiral and the head 
domain. Both σ1 constructs included the predicted carbohydrate-binding site (8). 
Crystals of σ1short and σ1long were formed using the single-drop-vapor-diffusion 
method. Once formed, crystals of σ1long were soaked in solution with GM2 to 
allow the glycan to bind. This approach yielded a 3.6 Å crystal structure of the T1 
σ1-GM2 complex. The crystal structure of this complex was solved by molecular 
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replacement using a 2.6 Å crystal structure of His-tagged σ1short as a reference 
model during refinement.  
The structure of the T1 σ1-GM2 complex revealed that the glycan-binding 
site is located within the head domain of σ1 (Figure III-1). All three monomers 
comprising the trimeric σ1 protein engage GM2 in an identical manner. Both the 
sialic acid (Neu5Ac) and GalNAc moieties of GM2 contact σ1 with the functional 
groups of sialic acid directly interacting with the protein. The carboxyl group of 
Neu5Ac forms a hydrogen bond with the side chain of Gln371, and the N-acetyl 
nitrogen and glycerol chain form hydrogen bonds with σ1 backbone residues. A 
methyl group of the N-acetyl side chain of sialic acid fits within a hydrophobic 
pocket flanked by Val354, Phe369, and Met372. While the majority of σ1 
contacts are with sialic acid, the GalNAc enhances binding through Van der 
Waals interactions and likely contributes to the specificity of T1 σ1 for GM2 
(Figure III-2). The finding that the majority of interactions between T1 σ1 and 
GM2 involve backbone elements and not side chains of the viral attachment 
protein is unprecendented in studies of virus-glycan binding (27) and 
necessitated confirmation using structure-guided mutagenesis to be certain that 
the binding site identified crystallographically was biologically relevant. 
The T1 glycan-binding site is in a region of σ1 distinct from the binding 
sites of other known reovirus receptors (Figure III-3A). While JAM-A also binds 
the σ1 head domain (152) (Kirchner-Stettner and Stehle, unpublished), the 
binding sites for JAM-A and GM2 do not overlap (Figure III-3B). Moreover, 
analysis of the crystal structures of T1 σ1 in complex with GM2 and T3 σ1 in  
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Figure III-1. Crystal structure of T1L σ1 in complex with the GM2 glycan. 
Ribbon tracing of the complex viewed from the side (A) with a close-up of the 
carbohydrate-binding site (B) and top-view of the complex (C). The three T1L σ1 
monomers are depicted in blue, red, and yellow. β-spiral repeats 1, 2, and 3 and 
β-strands A-H are labeled. The GM2 oligosaccharide is shown in stick 
representation, with carbons, oxygens, and nitrogens colored yellow, red, and 
blue, respectively.  
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Figure III-2. The carbohydrate-binding site of T1L σ1. (A) Surface 
representation of T1L σ1 shown in light gray. The GM2 glycan is depicted in stick 
representation with the two terminal sugars, Neu5Ac and GalNAc, that contact 
T1L σ1 shown in color, and the Gal and Glc residues shown in gray. (B) Close-
up view of the Neu5Ac-binding pocket, with contacting residues shown in stick 
representation in blue (carbons) and the protein surface shown in light gray. 
Neu5Ac is depicted in stick representation and colored as in Figure 1. Hydrogen 
bonds between T1L σ1 and Neu5Ac are represented with black dashes. The 
methyl group of the N-acetyl chain of Neu5Ac inserts into a hydrophobic pocket 
formed by residues Val354, Phe369, and Met372.  
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Figure III-3. Comparison of the σ1-receptor binding sites. ( A) Schematic 
representation of σ1 domain organization. Binding sites in T1L and T3D σ1 for 
JAM-A and carbohydrate are depicted in green and pink, respectively. Surface 
representations of (B) T1L σ1 in complex with the GM2 glycan (PDB accession 
code 4GU3) and (C) T3D σ1 in complex with the GM3 glycan (also known as 3’ 
sialyllactose) (PDB accession code 3S6X). The carbohydrates are shown in stick 
representation and colored as in Figure 1. The JAM-A-binding sites are 
highlighted in green, and the carbohydrate-binding sites in T1L and T3D σ1 are 
depicted in pink and purple, respectively. (D) Sequence alignment of the T3 
carbohydrate-binding site in T1L and T3D σ1. Residues required for 
carbohydrate engagement in T3D σ1 are highlighted in blue. Residue Arg202, 
which forms a central interaction with Neu5Ac in T3D σ1, is marked with a blue 
dot.  
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complex with 3’SL, also known as the GM3 glycan, sheds light on the serotype 
specificity of reovirus carbohydrate-interactions, as both serotypes bind distinct 
glycans using different regions of the attachment protein. T3 σ1 binds sialic acid 
(9) using sequences within the body domain (Figure III-3C). While the T1 σ1 
construct used in the Stehle lab crystallography studies did not include this 
region (Figure III-3B), sequence analysis suggests that the region of T1 σ1 
corresponding to the T3 glycan-binding site could not bind sialic acid, as T1 σ1 
lacks a key arginine residue required for the interaction (Figure III-3D). Alignment 
of the T1 and T3 σ1 structures suggests that the region in the T3 σ1 head 
domain corresponding to the T1 σ1 GM2-binding site could not bind GM2 due to 
steric hindrance (Figure III-4), thereby confirming results obtained using soluble 
GM2 to inhibit reovirus infection (Figure II-6A). These findings also provide a 
framework to engineer mutants with alterations in the T1 σ1 glycan-binding site.  
 
Single-residue mutant design 
Kerstin and I worked together to rationalize mutations in T1 σ1 that would 
disrupt the σ1-GM2 complex. Since single point mutations ablate the binding of 
T3 σ1 to sialic acid (7, 9, 24, 154), we designed a panel of T1 viruses that 
differed from wildtype by a single residue within the putative glycan-binding 
domain (Table III-1). Residues Val354, Ser370, Gln371, and Met372 were 
selected for mutational analysis as a consequence of their proximity to the T1 σ1 
GM2-binding site. Val354 was replaced with phenylalanine and leucine residues  
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Figure III-4. The head domain of T3D σ1 does not bind Neu5Ac. (A) Surface 
representation of T1L σ1 depicted in gray. (B) Superposition of T1L (gray) and 
T3D (cyan) σ1. The GM2 glycan is shown in stick representation (colored as in 
Figure 2) in both panels. Clashes between the carbohydrate and T3D σ1 are 
highlighted with red circles in panel B. Both the Neu5Ac and GalNAc moieties of 
the GM2 glycan would clash with T3D σ1 residues.  
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Table III-1. Single-residue T1 σ1 mutant viruses. The position of the T1L 
residues (red) altered in the panel of single point mutants is shown. Some 
mutants contain residues found in the corresponding site in T3D (blue) and 
others represent changes (black) predicted to block GM2 binding.  
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that we hypothesized would block the sialic-acid-binding pocket through steric 
hindrance. The S370P, Q371A, and M372F mutants were engineered to replace 
the T1 σ1 residue with the corresponding residue in T3 σ1. The M372L 
substitution is a more conservative mutation than M372F and might not disrupt 
folding of the σ1 head. Point mutant Q371E was designed with an acidic residue 
to introduce a negative charge, which was predicted to repel the negatively 
charged sialic acid.  
 
Characterization of the σ1 point mutants 
I sought to identify T1 σ1 mutants that displayed impaired 
hemagglutination capacity and infectivity in MEFs. However, such alterations 
might be attributable to some unrelated defect in viral fitness other than 
diminished glycan binding. To eliminate the former possibility, I quantified viral 
replication in L cells, which do not require functional GM2 binding for infectivity 
and evaluated the capacity of a conformation-specific monoclonal antibody to 
block infection. L cells were adsorbed with wildtype or mutant viruses, and viral 
yields were quantified by plaque assay 24, 48, and 72 hours post-inoculation. 
Mutants V354L, S370P, Q371E, M372F, and M372L replicated similarly to 
wildtype virus in L cells, while V354F and Q371A showed a slight, albeit 
insignificant, impairment at 24 hours (Figure III-5). To establish whether the 
mutant σ1 proteins are properly folded, I tested T1 σ1 conformation-specific 
monoclonal antibody 5C6 for the capacity to neutralize infection by wildtype and 
mutant viruses in L cells. Escape mutants for this antibody display sequences  
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Figure III-5. Replication of the single-residue T1 σ1 mutant viruses in L 
cells. L cells were adsorbed with the strains shown at an MOI of 0.1 PFU/cell at 
room temperature for 1 h. Cells were washed with PBS, and fresh medium was 
added. Cells were frozen at 0, 24, 48, and 72 h post-adsorption, and viral titer 
was quantified by plaque assay. Results are expressed as the mean log10 viral 
yield from a representative experiment of two independent experiments, each 
performed in triplicate. Error bars represent standard deviation. *, P < 0.05, as 
determined by two-way ANOVA followed by Bonferroni’s multiple comparison 
test.  
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changes at Gln417 and Gly447 in T1 σ1 (155). These residues are located on 
the upper portion of the T1 σ1 head domain, near the intersubunit interface and 
distinct from the glycan-binding site (Figure III-6A). 5C6 is a conformation-
specific monoclonal antibody that likely binds a trimeric form of the T1 σ1 head 
domain. Recognition and neutralization by 5C6 indicates the presence of 
properly folded and assembled trimeric T1 σ1 head. Preincubation with mAb 5C6 
diminished the capacity of wildtype and all mutant viruses to infect L cells (Figure 
III-6B), suggesting that the head domain of the mutants is properly folded.  
To test whether these mutant viruses have an altered capacity to infect 
cells that are maximally susceptible to glycan-binding reovirus strains, I 
quantified infectivity using MEFs. MEFs were inoculated with wildtype and mutant 
viruses at an MOI of 1 FFU/cell as determined in assays using L cells. The 
V354F, S370P, Q371A, and Q371E mutants displayed a significant defect in 
infectivity in MEFs, suggesting that these residues influence glycan engagement. 
Infectivity of the V354L, M372F, and M372L mutants did not differ statistically 
from that of wildtype virus (Figure III-7). I also used hemagglutination assays as a 
proxy for glycan binding (137) and found that all of the mutants had a defect in 
the capacity to agglutinate human erythrocytes, with V354F, V354L, S370P, 
Q371A, and Q371E showing the greatest impairment (Figure III-8). However, 
hemagglutination capacity by these mutants is diminished but not ablated, as is 
the case for T3 mutants defective in glycan binding (9). This observation raises 
the possibility that the T1 σ1 single-residue mutants may retain glycan-binding  
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Figure III-6. Single-residue T1 σ1 mutant viruses are neutralized by mAb 
5C6. (A) Top-view of T1L σ1 (gray) in complex with the GM2 glycan (yellow). 
Residues Gln417 and Gly447 (Helander and Nibert REF), which are altered in 
mAb 5C6-resistant mutants and likely form part of the 5C6 epitope, are shown in 
stick representation in pink. (B) Wildtype and mutant viruses were incubated with 
conformation-specific T1L σ1-specific mAb 5C6 at room temperature for 1 h, and 
the virus-antibody mixture was adsorbed to L cells at room temperature for 1 h. 
Cells were washed twice with PBS, and fresh medium was added. After 
incubation at 37°C for 20 h, cells were fixed, and reovirus antigen was detected 
by indirect immunofluorescence. Nuclei were stained with DAPI. The percentage 
of infected cells in three fields of view per well was determined. Results are 
expressed as the mean infectivity per well from three independent experiments, 
each performed in triplicate. Error bars represent standard error of the mean. ***, 
P < 0.001, as determined by two-way ANOVA followed by Bonferroni’s multiple 
comparison test.  
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Figure III-7. Infectivity of single-residue T1 σ1 mutant viruses in MEFs. 
Monolayers of MEFs were adsorbed with the strains shown at an MOI of 1 
FFU/field (as titered on L cells) at room temperature for 1 h. Cells were washed 
twice with PBS, and fresh medium was added. After incubation at 37°C for 20 h, 
cells were fixed, and reovirus antigen was detected by indirect 
immunofluorescence. Nuclei were stained with DAPI. The percentage of infected 
cells in three fields of view per well was determined. The results are expressed 
as the percent infected cells from a representative experiment of three 
experiments, each performed in triplicate. Error bars represent standard 
deviations. ***, P < 0.01, as determined by one-way ANOVA followed by 
Bonferroni’s multiple comparison test.  
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Figure III-8. Hemagglutination by single-residue T1 σ1 mutant viruses. 
Purified virions of the strains shown (1011 particles/well) were serially diluted 1:2 
in PBS in 96-well U-bottom plates. Human erythrocytes were washed several 
times with PBS, resuspended to a concentration of 1% (vol/vol) in PBS, added to 
virus-containing wells, and incubated at 4oC for 3 h. Results are expressed as 
log2 (HA titer) from three independent experiments. HA titer is defined as 10
11 
particles divided by the number of particles/HA unit. One HA unit is the particle 
number sufficient to produce hemagglutination. *** P < 0.001, as determined by 
one-way ANOVA followed by Bonferroni’s multiple comparison test.  
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activity. Therefore, I engineered a second panel of multiple-residue mutants with 
the goal of identifying a virus that does not bind GM2. Moreover, I planned to use 
such a virus for in vivo studies, and the introduction of multiple mutations in σ1 
would make it more difficult for the virus to potentially revert to wildtype in mice.  
 
Design of multiple-residue mutants 
Using site-directed mutagenesis, I, along with the consultative assistance 
of Kerstin Reiss, designed a panel of viruses containing multiple mutations within 
the GM2-binding site (Table III-2). The S370P/Q371E mutant combined two of 
the most effective single-residue mutants that displayed impaired 
hemagglutination and infection of MEFs but infected L cells comparable to 
wildtype virus. The S370P/Q371A mutant was designed to exchange two native 
T1 σ1 residues to those in T3 σ1. The S370P/Q371A/M372F virus added an 
additional residue from T3 σ1. The S370P/Q371A/M372F/T374G mutant 
exchanged much of one of the β strands in T1 σ1 that interact with GM2 with the 
corresponding T3 residues. The T374G mutation was added because the M372F 
single-residue mutant virus had a slight replication defect in L cells, and T3D 
contains a glycine at the position corresponding to residue 374. We hypothesized 
that addition of this glycine residue would provide more room for the bulky 
phenylalanine residue and hopefully restore full replication capacity in L cells. 
Similarly, the full β-strand exchange mutant, 
F369L/S370P/Q371A/M372F/T374G, also would provide additional space for the 
proline at the amino-terminal end of the β strand and render the protein even  
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Table III-2. Multiple-residue T1 σ1 mutant viruses. The position of the T1L 
residues (red) altered in the panel of single point mutants is shown. Some 
mutants contain residues found in the corresponding site in T3D (blue) and 
others represent changes (black) predicted to block GM2 binding. 
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more like T3 σ1. All of the mutants were rescued by reverse genetics and 
working stocks of virus were prepared using L cells.  
 
Characterization of the multiple-residue mutants 
Viral infectivity experiments revealed that most of the multiple-residue 
mutant viruses replicated similarly to wildtype T1L in L cells (Figure III-9). 
However, when grown in parallel, titers of purified stocks of 
F369L/S370P/Q371A/M372F/T374G were repeatedly 100- to 1000-fold lower 
than those of T1L and the other mutants. This finding suggests that this virus has 
defects in viral replication independent of GM2 engagement. To specifically 
assess folding of the σ1 head, I evaluated the capacity of conformation-specific 
monoclonal antibody 5C6 to block wildtype and mutant virus infectivity, as was 
done for the single-residue mutants. T1L, S370P/Q371A, S370P/Q371E, 
S370P/Q371A/M372F, and S370P/Q371A/M372F/T374G were neutralized by 
the antibody (Figure III-10). The F369L/S370P/Q371A/M372F/T374G mutant was 
not completely neutralized by 5C6, suggesting that the head domain is not 
properly folded. Closer inspection of the crystal structure revealed that Phe369 is 
involved in an aromatic stacking interaction with Trp461 on the neighboring β 
strand. Disruption of that phenylalanine likely disrupts this interaction and 
consequentially alters the overall conformation of the σ1 head domain (Kerstin 
Reiss, personal communication).  
To test whether the mutants have impaired sialic acid binding, I quantified  
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Figure III-9. Replication of the multiple-residue T1 σ1 mutant viruses in L 
cells. L cells were adsorbed with the strains shown at an MOI of 0.1 PFU/cell at 
room temperature for 1 h. Cells were washed with PBS, and fresh medium was 
added. Cells were frozen at 0, 24, 48, and 72 h post-adsorption, and viral titer 
was quantified by plaque assay. Results are expressed as the mean log10 viral 
yield from a representative experiment of two independent experiments, each 
performed in triplicate. Error bars represent standard deviation. ** PI < 0.01 as 
determined by two-way ANOVA followed by Bonferroni’s multiple comparison 
test.  
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Figure III-10. Multiple-residue T1 σ1 mutant viruses are neutralized by mAb 
5C6. T1L, T3D, and multiple-residue T1 σ1 mutant viruses were incubated with 
T1L σ1-conformation-specific mAb 5C6 at room temperature for 1 h, and the 
virus-antibody mixture was adsorbed to L cells for 1 h. Cells were washed twice 
with PBS, and fresh medium was added. After incubation at 37°C for 20 h, cells 
were fixed, and stained with Alexa-647-labeled polyclonal reovirus antisera. The 
percentage of infected cells was quantified using flow cytometry. The data shown 
are a representative experiment of two independent experiments each performed 
in triplicate. Error bars represent standard deviation. ***, P < 0.001, as 
determined by two-way ANOVA followed by Bonferroni’s multiple comparison 
test.   
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hemagglutination titers of the wildtype and mutant viruses using human 
erythrocytes. The S370P/Q371A, S370P/Q371E, S370P/Q371A/M372F, and 
S370P/Q371A/M372F/T374G mutants displayed significantly diminished 
hemagglutination titers relative to wildtype (Figure III-11). However, like the 
single-residue mutants, the multiple-residue mutants retained a degree of 
hemagglutination capacity. Moreover, the magnitude of the hemagglutination titer 
difference between wildtype and mutant viruses was the same for the single- and 
multiple-residue mutants. The F369L/S370P/Q371A/M372F/T374G mutant 
lacked the capacity to agglutinate human erythrocytes. However, this mutant was 
removed from further study due to the defects observed in infectivity experiments 
using L cells and difficulties preparing high-titer stocks. The S370P/Q371E 
mutant was selected for further characterization.  
The S370P/Q371E virus as well as the S370P and Q371E single-residue 
mutants replicated well in L cells (Figure III-5) and were neutralized by 
conformation-specific monoclonal antibody 5C6 (Figure III-6). Stocks of these 
double and single mutants consistently produced titers approximating those of 
wildtype T1L. The S370P/Q371E mutant was selected over the S370P/Q371A 
mutant because the Q371A single mutant had a slight defect in replication in L 
cells and, more importantly, steric hindrance caused by the introduction of a 
proline at residue 370 coupled with a negative charge associated with the 
introduction of a glutamic acid at residue 371 was thought more likely to repel 
GM2 binding compared with an alanine at 371. It is possible that any of the 
multiple-residue mutants would have been equally compromised in GM2-binding  
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Figure III-11. Hemagglutination by σ1 mutant viruses. Purified virions of the 
strains shown (1011 particles/well) were serially diluted 1:2 in PBS in 96-well U-
bottom plates. Human erythrocytes were washed several times with PBS, 
resuspended to a concentration of 1% (vol/vol) in PBS, added to virus-containing 
wells, and incubated at 4oC for 3 h. Results are expressed as log2 (HA titer) from 
three independent experiments. ***, P < 0.001, as determined by one-way 
ANOVA followed by Bonferroni’s multiple comparison test.  
65 
 
capacity relative to S370P/Q371E, but only one virus was selected for in vivo 
experiments. Further characterization using saturation-transfer difference nuclear 
magnetic resonance (STD-NMR) demonstrated that the S370P/Q371E mutant is 
incapable of binding GM2, but if this had not been the case, I would have 
returned to this mutant panel and further characterized additional mutant viruses.  
The S370P/Q371E double mutant, like the S370P and Q371E single 
mutants, displayed impaired hemagglutination capacity compared with wildtype 
T1L. However, unlike T3 sialic acid-binding mutants, which do not have the 
capacity to agglutinate erythrocytes (9) the T1 σ1 mutants altered in GM2-binding 
still produce hemagglutination (Figures III-8 and III-11), albeit at reduced levels 
compared with wildtype virus. While T1 reovirus mediated-agglutination of human 
erythrocytes is known to be glycan-dependent (137), the influence of 
neuraminidase treatment on T1 reovirus-induced hemagglutination had not been 
reported. Neuraminidase treatment ablates T3 reovirus mediated-
hemaggulatination (156). Therefore, I performed a hemagglutination inhibition 
(HAI) assay using 4 hemagglutination units, where 1 hemagglutination unit is 
defined as the minimal number of viral particles required to produce 
hemagglutination. Strains T1L or S370P/Q371E were incubated with erythrocytes 
that had been treated with either A. ureafaciens neuraminidase to remove cell-
surface sialic acid or PBS as a vehicle control. T1L-mediated hemagglutination 
was impaired following neuraminidase treatment, while S370P/Q371E 
agglutination capacity was not affected (Figure III-12A). This finding suggests 
that T1L, but not S370P/Q371E, binds sialic acid to agglutinate human  
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Figure III-12. Neuraminidase diminishes hemagglutination capacity of T1L 
but not S370P/Q371E. (A) Human erythrocytes were washed with PBS, 
resuspended at a concentration of 1% (vol/vol), and treated with PBS (vehicle 
control), T1L σ1-conformation-specific mAb 5C6, or 200mU of A. ureafaciens 
neuraminidase (NM) at room temperature for 1 h prior to adsorption with 4 HA 
units of the virus strains shown in 96-well U-bottom plates. Erythrocytes were 
incubated with virions at 4oC for 3 h. The data shown are a representative of 
three independent experiments. (B) Human erythrocytes were washed with PBS, 
resuspended at a concentration of 1% (vol/vol), and treated with PBS (vehicle 
control) or 200 mU of A. ureafaciens neuraminidase at room temperature for 1 
hour prior to distribution into wells of 96-well U-bottom plates containing 1011 
purified virions of T1L or S370P/Q371E serially diluted 1:2 in PBS. Plates were 
incubated at 4°C for 3 h. Results are expressed as log2 HA titer from three 
independent experiments. Error bars represent standard deviation (S.D.) * p 
<0.05, as determined by two-way ANOVA followed by Bonferroni’s multiple 
comparison test.  
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erythrocytes. Furthermore, the residual hemagglutination capacity of 
S370P/Q371E is likely due to interactions with non-sialylated receptors on the 
erythrocyte surface. 
One caveat of performing a standard HAI assay with two different virus 
strains is that 4 HA units, standard in these assays, represents different 
concentrations of viral particles for T1L and S370P/Q371E because the wildtype 
virus agglutinates erythrocytes more efficiently than does the mutant. Therefore, 
to further evaluate the influence of neuraminidase on T1 reovirus 
hemagglutination, I performed a standard hemagglutination assay and quantified 
HA titer using erythrocytes that had been pre-treated with either A. ureafaciens 
neuraminidase or PBS. Neuraminidase treatment abolishes the hemagglutination 
capacity of T3 reovirus as expected (156). However, neuraminidase treatment 
only diminishes the capacity of T1 reovirus to agglutinate human erythrocytes. 
Moreover, the capacity of T1L to agglutinate neuraminidase-treated erythrocytes 
approximated the capacity of S370P/Q371E to agglutinate PBS-treated 
erythrocytes. The hemagglutination capacity of S370P/Q371E was not further 
reduced by treatment of the erythrocytes with neuraminidase (Figure III-12B). 
Taken together, these findings suggest that T1L binds to sialylated glycans on 
erythrocytes, while S370P/Q371E does not.  
To determine whether the S370P/Q371E mutation is incapable of 
engaging GM2, I collaborated with Bärbel Blaum in the Stehle lab to assess the 
binding of wildtype T1L, S370P, Q371E, and S370P/Q371E σ1 proteins to GM2 
in solution using NMR spectroscopy. This approach is well suited to study low-
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affinity interactions between a large molecule, such as σ1, and a small ligand, 
such as the GM2 glycan (157, 158). As anticipated, T1L σ1 engaged GM2 in 
solution, consistent with our previous results (10). The GM2 protons specifically 
in the GalNAc and sialic acid moieties interact with σ1, mimicking the binding 
contacts in the crystal structure. While the S370P and Q371E single-residue 
mutant σ1 proteins minimally interacted with the GM2 glycan in solution, we did 
not detect binding of the S370P/Q371E double-mutant σ1 protein to the GM2 
glycan (Figure III-13).  
To determine whether the S370P/Q371E mutant virus has altered capacity 
to infect cells in a carbohydrate-dependent manner, I quantified infectivity using 
MEFs, which require GM2 for optimal infection. MEFs were inoculated with T1L 
or S370P/Q371E at a range of MOIs as determined in assays using L cells. 
S370P/Q371E displayed diminished capacity to infect MEFs compared with T1L 
at all MOIs tested (Figure III-14). This finding suggets that S370P/Q371E does 
not interact with GM2 on the MEF cell-surface and consequentially infects these 
cells less efficiently than T1L.  
To establish whether the difference in infectivity displayed by wildtype and 
mutant viruses in MEFs resulted from compromised viral attachment, T1L and 
S370P/Q371E were adsorbed to MEFs and L cells at 4°C to prevent 
internalization, and the percentage of cells with bound virus was quantified using 
flow cytometry. Both T1L and S370P/Q371E bound equally well to L cells, but  
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Figure III-13. Binding of T1L and S370P/Q371E to the GM2 glycan. STD NMR 
spectroscopy demonstrates that the WT T1L σ1 binds to the GM2 glycan in 
solution. Single S370P and Q371E mutants and the double S370P/Q371E 
mutant σ1 proteins bind minimally or not at all, respectively. From top to bottom: 
STD spectrum of T1L σ1 and GM2 glycan, GM2 glycan alone, S370P mutant σ1 
and GM2, Q371E mutant σ1 and GM2, and S370P/Q371E double mutant σ1 and 
GM2. Resonances that can be unambiguously assigned to individual protons are 
labeled and color-coded according to the sugar moieties within the GM2 glycan: 
glucose (Glc), yellow; galactose (Gal), green; neuraminic acid (red); and N-
acetylgalactosamine (GalNAc), blue.  
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Figure III-14. Infectivity of T1L and S370P/Q371E in MEFs. Monolayers of 
MEFs were adsorbed with the strains shown at an MOI of 1 FFU/field (as titered 
on L cells) at room temperature for 1 h. Cells were washed twice with PBS, and 
fresh medium was added. After incubation at 37°C for 20 h, cells were fixed, and 
reovirus antigen was detected by indirect immunofluorescence. Nuclei were 
stained with DAPI. The percentage of infected cells in three fields of view per well 
was determined. The results are expressed as the percent infected cells from the 
combined means of three independent experiments each performed in triplicate 
wells. Error bars represent standard error of the mean. * P <0.05, ** P < 0.01, *** 
P < 0.001, as determined by two-way ANOVA followed by Bonferroni’s multiple 
comparison test.  
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S370P/Q371E adhered less efficiently to MEFs in comparison to T1L (Figure III-
15). Thus, S370P/Q371E has a defect in attachment to and infectivity of host 
cells that require glycan engagement for optimal infection. 
 
Discussion 
Studies reported in this chapter defined the σ1-GM2 binding site and 
identified residues required for functional GM2 engagement. Using NMR 
spectroscopy and crystallography, we determined that the head domain of T1 σ1 
contacts the sialic acid and GalNAc moieties of GM2 (Figures III-1, III-2, and III-
13). Structure-guided, site-directed mutagenesis revealed that residues Val354, 
Ser370, and Gln371 are required for functional glycan binding. Mutation of single 
or multiple residues within the glycan-binding site diminishes hemagglutination 
and infectivity in MEFs. Additionally, a T1 reovirus engineered with both S370P 
and Q371E mutations in σ1 is incapable of binding GM2 (Figure III-13) and 
displays diminished capacity to attach to the MEF cell-surface (Figure III-15).  
The crystal structure of the T1 σ1-GM2 complex revealed that the 
carbohydrate-binding site is located within the head domain of the attachment 
protein. Yet, GM2 and JAM-A bind distinct regions of the T1 σ1 head domain, 
making it possible for both receptors to be bound simultaneously (Figures III-2 
and III-3). Reovirus engagement of host cells is likely a multistep process in 
which interactions with glycans function in adhesion strengthening (7). In support 
of this idea, the NMR data (Figure III-13) coupled with the high doses of GM2 
required to block T1 reovirus infection (Figure II-6) suggest that the virus binds  
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Figure III-15. The capacity of T1L and S370P/Q371E to bind MEFs. MEFs 
were adsorbed with the virus strains shown at an MOI of 5 x 104 particles per cell 
at 4°C for 1 h. Cells were washed twice with PBS and stained with Alexa-647-
labeled reovirus antiserum. The percentage of cells with bound virus was 
quantified using flow cytometry. Results are a representative experiment of three 
independent experiments, each performed in triplicate. *** P < 0.001 as 
determined by two-tailed student’s t test.  
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GM2 with relatively low affinity compared with the high-affinity binding of reovirus 
to JAM-A. Additionally, glycan binding is required for T1 reovirus infection of 
MEFs, which express modest levels of JAM-A, and dispensable for infection of L 
cells, which express significantly higher JAM-A levels (Figure II-2). 
T1 and T3 reovirus bind sialylated carbohydrates using entirely different 
domains of σ1. Steric hindrance would prevent the T3 σ1 protein from engaging 
GM2 in the region corresponding to the glycan-binding domain of T1 σ1. This 
observation is in accordance with my finding that GM2 blocks T1 but not T3 
reovirus infection of MEFs (Figure II-6). While the crystal structure of T1 σ1 does 
not contain the region corresponding to the T3 σ1 sialic acid-binding site, 
sequence analysis suggests that the body domain of T1 σ1 is unlikely to engage 
sialic acid. T1 σ1 contains an aspartate at the location in which T3 σ1 contains an 
arginine residue (Figure III-3D) that contacts sialic acid. Mutation of this arginine 
at residue 202 in the T3 σ1 body domain disrupts the bidentate salt bridge 
between the arginine side chain and the sialic acid carboxylate and renders the 
virus incapable of binding sialylated glycan (9). We predict that the negatively 
charged aspartate residue would repel sialic acid and thereby prevent the body 
domain of T1 σ1 from engaging the negatively charged sialic acid.  
 The crystal structure of the T1 σ1-GM2 binding site demonstrates that the 
sialic acid (Neu5Ac) and GalNAc contact the protein. The majority of the contacts 
are contributed by Neu5Ac through hydrogen bonds with the backbone of T1 σ1, 
while the GalNAc docks onto a shallow pocket using van der Waals interactions. 
This finding was unexpected, as side chains are commonly involved in virus 
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attachment protein-carbohydrate interactions (27). To provide biological evidence 
to support these structural findings, I engineered mutants using reverse genetics 
and identified residues required for glycan engagement on host cells. The single-
residue mutant viruses displayed impaired hemagglutination capacity (Figure III-
8) and infectivity in MEFs (Figure III-7), with substitutions of Val354, Ser370, and 
Gln371 having the greatest effects. Residue V354 flanks a hydrophobic pocket 
into which the methyl group of the N-acetyl chain of Neu5Ac inserts. The S370P 
substitution introduces a protruding and rigid ring structure, which is expected to 
cause steric hindrance within the glycan-binding pocket. Gln371 likely forms a 
hydrogen bond with the carboxyl group of Neu5Ac. In the point mutants Q371E 
and Q371A, this hydrogen bond would be lost, resulting in reduced affinity for 
ligand and, in the case of Q371E, electrostatic repulsion. Taken together, these 
findings indicate that V354, S370, and Q371 are required for functional GM2 
engagement.  
 The single point mutants retained some capacity to agglutinate red blood 
cells, suggesting that either these mutants retained some sialic-acid-binding 
capacity or engagement of alternative receptors contributes to hemagglutination 
capacity. I therefore generated a panel of multiple-residue mutants in an attempt 
to further compromise glycan binding. These mutants did not display a further 
decrease in hemagglutination capacity or infectivity in MEFs compared with the 
single-residue mutants (Figures III-8 and III-11). We used NMR spectroscopy to 
determine whether the mutants retained residual GM2 binding capacity. The 
S370P and Q371E single mutants display minimal, if any, interaction with GM2 in 
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solution, while the S370P/Q371E double mutant does not interact with the glycan 
at all (Figure III-13). Thus, introduction of multiple mutations in the T1 σ1 glycan-
binding site only slightly diminishes glycan-binding, if at all, relative to the single-
residue mutants.  
From these data, I conclude that cell-surface structures in addition to 
glycans contribute to T1 reovirus-mediated agglutination of human erythrocytes. 
Hemagglutination by T1 reovirus is carbohydrate-dependent, as sodium 
periodate decreased hemagglutination capacity (137). While neuraminidase 
treatment abolishes T3-mediated agglutination of human erythrocytes (156) 
(Figure III-12), such treatment diminishes the HA titer of T1L to levels 
approximating those of the glycan-binding-site mutants (Figure III-12). Type O 
erythrocytes were used in these studies, yet reovirus agglutinates erythrocytes 
from all blood groups (159), suggesting that human blood group antigens are not 
required for erythrocyte agglutination. Of note, reovirus receptor JAM-A is 
expressed on erythrocytes (160) and may mediate hemagglutination, although 
this possibility has not been formally tested.  
  These studies with T1 reovirus support a general principle observed for 
other viruses, including influenza virus (47, 161-163), polyomaviruses (51, 74), 
and T3 reovirus (7, 9, 24), that few mutations are required to disrupt virus-sialic 
acid interactions. Viruses containing mutations in the sialyloligosaccharide-
binding site are valuable tools to determine the function of sialylated glycan 
binding in tropism and pathogenesis. A T1 reovirus containing S370P and Q371E 
mutations cannot bind GM2 and was selected for in vivo studies to investigate 
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the contribution of GM2 engagement to reovirus-mediated disease. This work is 
described in Chapter IV.  
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CHAPTER IV 
 
THE FUNCTION OF GM2 BINDING IN SEROTYPE 1 REOVIRUS 
PATHOGENESIS 
 
Introduction 
 Reovirus disseminates with serotype-specific tropism in neonatal mice, but 
the basis for serotype-specific neurologic disease is not known. T1 reovirus 
infects ependymal cells and causes hydrocephalus (16, 105, 106), whereas T3 
reovirus infects neurons and causes lethal encephalitis (140, 164). Reassortant 
viruses containing a T1 S1 gene cause hydrocephalus whereas viruses 
containing a T3 S1 gene cause encephalitis (114). This observation suggests 
that differences in receptor engagement contribute to serotype-specific tropism.  
JAM-A serves as a receptor for T1 and T3 reoviruses (11, 125, 152, 165) 
and is required for hematogenous reovirus spread (12) (Lai and Dermody, 
unpublished). However, JAM-A is dispensable for reovirus infection in the brain 
and, therefore, cannot account for serotype-specific patterns of reovirus-induced 
neurologic disease (12). T3 reoviruses differing only in the capacity to bind sialic 
acid display striking differences in tropism particularly within the bile duct 
epithelium (139) and CNS (140). When I began this project, the contribution of T1 
σ1-glycan interactions to disease was not known. This knowledge gap precluded 
a precise understanding of reovirus tropism and the basis of serotype-specific 
disease phenotypes. While the tissue distribution of GM2 is not known, this 
glycan is a component of the mammalian nervous system (166-169), suggesting 
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that reovirus engagement of GM2 influences serotype-specific neurologic 
disease. Through genetic manipulation of reovirus and the murine host, I 
investigated the effect of GM2 engagement by T1 reovirus on systemic viral 
dissemination and hydrocephalus, the cardinal T1 reovirus disease 
manifestation.  
Using structure-guided mutagenesis, I engineered a T1L mutant virus 
containing S370P and Q371E mutations in σ1. The σ1-S370P/Q371E protein 
does not interact with GM2 in solution (Figure III-13). Moreover, this mutant virus 
displays diminished hemagglutination capacity and impaired binding to and 
infection of MEFs (Figure III-14), which are optimally susceptible to sialic acid-
binding reovirus strains (Figure II-1). The S370P/Q371E mutant replicates 
efficiently in L cells, which are equally susceptible to strains that differ in sialic-
acid-binding capacity. I used mice that lack expression of the GM2 glycan in a 
few experiments to complement studies using the S370P/Q371E mutant virus. 
I collaborated with Dr. Daniel Colvin at the Vanderbilt Small Animal 
Imaging Core to use magnetic resonance imaging (MRI) to quantify the severity 
of hydrocephalus after reovirus infection. Daniel designed a program in MatLab 
that I used to quantify the ventricular volume (Figure IV-6). I worked with Dr. Ty 
Abel, a Vanderbilt neuropathologist, to evaluate histological changes in brain 
tissue of reovirus-infected animals. He obtained images presented in Figure IV-4. 
I also worked with Dr. Kelli Boyd, a Vanderbilt veterinary pathologist, to evaluate 
regions of the brain targeted by reovirus. She obtained the images presented in 
Figure IV-3.  
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Results 
Analysis of viral load and disease using viruses that differ in the capacity to bind 
GM2 
 
To define the function of T1 σ1-GM2 interactions in viral dissemination 
and disease, I inoculated two-to-three day old wildtype C57Bl/6 mice perorally 
with 102 PFU of either wildtype T1L or the σ1-S370P/Q371E mutant virus. The 
intestine, mesenteric lymph nodes (MLN), spleen, liver, heart, and brain were 
excised 4, 8, and 12 days post-inoculation, and viral titer was quantified by 
plaque assay. Wildtype and mutant viruses produced comparable titers in the 
intestine, MLN, spleen, liver, and heart. However, T1L produced slightly higher 
titers in the brain compared with S370P/Q371E, although these differences were 
not statistically significant (Figure IV-1). The magnitude of this difference in viral 
loads in the brain is similar to that observed between T3 reoviruses differing in 
sialic-acid-binding capacity (139, 140).  
To determine whether the lower viral titer in the brain following inoculation 
with S370P/Q371E was a result of diminished dissemination to the brain or 
replication at that site, wildtype mice were inoculated intracranially with 102 PFU 
of either T1L or S370P/Q371E. Brain homogenates were titered by plaque assay 
4, 8, and 12 days post-inoculation (Figure IV-2A). Concordant with differences in 
viral titer after peroral inoculation, T1L produced higher titers in the brain 
compared with S370P/Q371E, reaching statistical significance on day 8 post-
inoculation. These findings suggest that T1 σ1-glycan interactions are required 
for optimal replication within the murine brain.  
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Figure IV-1. Viral titers in various organs following peroral inoculation with 
either T1L or S370P/Q371E. Newborn C57BL/6 mice were inoculated perorally 
with 102 PFU of either T1L or S370P/Q371E. At days 4, 8, and 12 post-
inoculation, mice were euthanized, and the intestine, heart, and brain were 
excised and homogenized. Viral titers in organ homogenates were quantified by 
plaque assay. Results are expressed as mean viral titers for 4 to 10 mice per 
virus strain per timepoint. Error bars represent standard error of the mean. 
Values were not statistically significant as quantified by a two-way ANOVA 
followed by Bonferroni’s multiple-comparison test.  
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Figure IV-2. Viral titers in the brain following intracranial inoculation with 
either T1L or S370P/Q371E. Newborn mice were inoculated intracranially with 
102 (A) or 108 (B) PFU of either T1L or S370P/Q371E. At days 4, 8, and 12 post-
inoculation, mice were euthanized, and brains were excised and homogenized. 
Viral titers in brain homogenates were determined by plaque assay. Results are 
expressed as mean viral titers for 4 to 11 mice per virus per timepoint. Error bars 
represent SEM. * P < 0.05 as determined two-way ANOVA followed by 
Bonferroni’s multiple-comparison test.  
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I next sought to assess the contribution of glycan-binding capacity to T1 
reovirus-mediated hydrocephalus. Higher doses of T1L are required to uniformly 
induce hydrocephalus (16, 17, 114, 116). Moreover, previous experiments used 
Balb/c or NIH Swiss Webster mice, which tend to be more susceptible to reovirus 
in comparison to C57Bl/6 mice (Boehme and Dermody, unpublished). Therefore, 
I increased the viral dose for studies of hydrocephalus induction. Wildtype mice 
were inoculated with 108 PFU of T1L or S370P/Q371E intracranially, and viral 
titers in brain homogenates were quantified 4, 8, and 12 days post-inoculation by 
plaque assay (Figure IV-2B). No significant differences in titer were observed, 
suggesting equivalent replication capacity of T1L and S370P/Q371E in the brain 
following intracranial inoculation at high doses (Figure IV-2B).  
Since the overall viral titer in the brain was equilibrated following high-
dose inoculation, we used histology to determine whether T1L and 
S370P/Q371E differ in tropism. Mice were inoculated in the right cerebral 
hemisphere with 108 PFU of T1L or S370P/Q371E and euthanized 4 and 12 days 
post-inoculation. The left hemisphere was excised and stained for reovirus 
antigen. Major differences in cells targeted by wildtype and mutant virus were not 
detected. However, evaluation of the samples by a pathologist blinded to the 
conditions of the experiment revealed that S370P/Q371E displayed less 
dissemination to the contralateral hemisphere compared with T1L at 4 days post-
inoculation (Figure IV-3). Although reovirus antigen was detected, hydrocephalus 
was not evident. Conversely, at 12 days post-inoculation reovirus antigen could 
no longer be detected in the brain, yet signs of pathologic injury were present.  
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Figure IV-3. Reovirus histology four days following intracranial inoculation 
with either T1L or S370P/Q371E.  
Newborn mice were inoculated intracranially with PBS or 108 PFU of T1L or 
S370P/Q371E. Four days-post-inoculation, mice were euthanized, and brains 
were excised, fixed, and paraffin embedded. Samples were stained with H&E 
(top) to examine tissue pathology. In the T1L sample, arrowheads indicate areas 
ependymal cell denuding. Arrows point toward sloughed cells in the ventricles, 
which may contribute to hydrocephalus. In the S370P/Q371E brain, focal malacia 
in the periventricular neurophil is observed. Arrows indicate regions of apoptotic 
neurons and glia with mild hemorrhage. Samples were stained with reovirus 
(bottom) antisera to detect viral antigen. Viral antigen is dispersed in the T1L-
infected brain, but more localized to the inoculation site in the S370P/Q371E-
infected brain.  
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Histological evaluation of brains from wildtype mice inoculated with T1L showed 
a disorganized choroid plexus with greater cell density within the ventricle 
compared with mice inoculated with PBS as a control. Moreover, cells in the 
PBS-inoculated mice are evenly spaced with pale, monomorphous nuclei, and 
abundant cytoplasm. Conversely, cells in the choroid plexus of the T1L-
inoculated mice are jumbled and display high nuclear to cytoplasm ratios. Brain 
samples from wildtype mice inoculated with S370P/Q371E showed evidence of 
disease but displayed more normal epithelial borders and lower cell density 
within the choroid plexus relative to that seen in T1L-infected animals (Figure IV-
4A). The sections were stained with Ki-67, which recognizes a nuclear protein 
expressed during the cell cycle, and is used as a marker for cellular proliferation 
(170, 171). Immunohistochemical analysis showed greater proliferation within the 
ventricle, evidenced by enhanced Ki-67 staining in the brains of wildtype mice 
inoculated with T1L compared with that observed in brains of mice inoculated 
with S370P/Q371E. Differences in apoptosis induction, evidenced by staining for 
activated caspase-3, were minimal (Figure IV-4B).  
To test whether GM2-binding capacity contributes to hydrocephalus, 
wildtype mice were inoculated intracranially with either T1L or S370P/Q371E. 
Hydrocephalus was assessed using MRI 21 days post-inoculation (Figure IV-5). 
Wildtype mice inoculated with T1L developed much more substantial 
hydrocephalus than those infected with S370P/Q371E. Quantification of the 
ventricular volume (Figure IV-6) confirmed that T1L induces a greater degree of 
hydrocephalus compared with S370P/Q371E in which ventricular volume did not  
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Figure IV-4. Brain histology twelve days following intracranial inoculation 
with either T1L or S370P/Q371E. Newborn mice were inoculated intracranially 
with PBS or 108 PFU of T1L or S370P/Q371E. Twelve days-post-inoculation, 
mice were euthanized, and brains were excised, fixed, and paraffin embedded. 
Samples were stained with H&E (A) to examine tissue pathology. Brain tissue of 
a mock (PBS) infected mouse displays a normal choroid plexus while the brain 
tissue of mice infected with wildtype virus (T1L) display a disorganized choroid 
plexus marked with enhanced cellular density within the capillary structure. The 
brain tissue of the mice infected with the mutant virus (S370P/Q371E) more 
closely resembles that of the PBS-inoculated mice. (B) Brain tissue was stained 
for reovirus antigen (left panel), Ki-67 as a marker for proliferation (middle panel), 
and caspase-3 (right panel). Reovirus antigen is not detectable in the choroid 
plexus at this time. The Ki-67 staining shows that T1L infected mice display 
enhanced proliferation within the capillary structure of the choroid plexus 
compared with mock and S370P/Q371E inoculated mice. The brown staining in 
the PBS-inoculated mice is outside of the capillary structure and likely represents 
a neural stem cell population. Caspase-3 staining is minimal.  
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Figure IV-5. Glycan binding capacity influences hydrocephalus induction. 
Wildtype and GM2-/- mice were inoculated intracranially with 108 PFU of T1L or 
S370P/Q371E. Twenty-one days post-inoculation, T2-weighted magnetic 
resonance images were obtained. Coronal images of representative wildtype 
mice inoculated with PBS (top left), wildtype mice inoculated with T1L (top right), 
wildtype mice inoculated with S370P/Q371E (bottom left), and GM2-/- mice 
inoculated with T1L (bottom right) are shown. Cerebrospinal fluid appears white, 
indicating inflammation of the ventricles. Images were obtained from mice with 
the medium ventricular volume (n = 4-10 mice per group).  
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Figure IV-6. Glycan binding capacity influences ventricular volume. 
Ventricular volume was quantified from MRI images of reovirus-infected mice as 
described in the Figure 4 legend using Matlab. Each symbol represents the 
ventricular volume from a single mouse. Mean ventricular volume is indicated 
with a horizontal bar. *, P < 0.05 as quantified by a one-way ANOVA followed by 
Bonferroni’s correction for multiple tests.  
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differ appreciably from mock-infected animals. This observation suggests that the 
capacity to bind GM2 enhances reovirus-mediated hydrocephalus.  
 
Analysis of reovirus-induced hydrocephalus in mice lacking GM2 expression 
To complement studies evaluating hydrocephalus induction by viruses that 
differ in the capacity to engage GM2, I analyzed the magnitude of hydrocephalus 
using mice that differ in expression of the GM2 glycan. I obtained mice that lack 
functional copies of the galgt1 and galgt2 genes on a C57Bl/6 background. The 
galgt1 and galgt2 genes encode the enzymes required to express the GM2 
glycan on gangliosides and glycoproteins, respectively (172). Thus, galgt1 x 
galgt2 double-knockout mice, herein referred to as GM2-/- mice, lack GM2 glycan 
expression on both gangliosides and glycoproteins (172, 173). These mice 
express GM3 but do not express gangliosides for which GM2 is a progenitor, 
such as GM1.  
To test whether GM2 binding contributes to hydrocephalus, wildtype and 
GM2-/- mice were inoculated intracranially with T1L, and hydrocephalus was 
assessed using MRI 21 days post-inoculation. The severity of T1L mediated 
hydrocephalus, evidenced by visual examination of the MRIs (Figure IV-5) and 
quantification of the ventricular volume, (Figure IV-6) was more severe in 
wildtype mice than in GM2-/- mice. Taken together, these studies demonstrate 
that disruption of the σ1-GM2 interaction through manipulation of the viral GM2-
binding site or host GM2 expression diminishes the severity of hydrocephalus 
caused by T1 reovirus. 
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The effect of GM2 binding capacity on viral dissemination and transmission 
The glycan-binding site is conserved in the T1 reovirus strains for which 
sequence information is available (Figure IV-7). Therefore, I considered the 
possibility that glycan-binding capacity confers a fitness advantage such as 
enhancing dissemination within a host or spread between hosts. To determine 
whether glycan binding enhances dissemination, I co-inoculated two-to-three-
day-old C57Bl/6 mice perorally with 102 PFU of T1L and 102 PFU of 
S370P/Q371E. Mice were euthanized 8 days post-inoculation and the intestine 
and brain were resected and homogenized. Organ homogenates were subject to 
plaque assay using L cells, and individual plaques from the intestine and brain of 
six mice were picked and passaged once in L cells prior to sequencing. T1L 
predominated in three of the six brains, while S370P/Q371E predominated in the 
remaining three brains (Figure IV-8A). A similar trend was observed in the 
intestine where T1L predominated in two of the six mice, and S370P/Q371E 
predominated in the remaining four mice (Figure IV-8B). Combined analysis of 
the virus stocks grown from the selected plaques demonstrates that both 
wildtype and mutant viruses are present in roughly equal proportion (Figure IV-
8C). These findings suggest that glycan binding capacity does not influence 
reovirus dissemination within a host.  
To determine whether GM2-binding capacity influences viral spread 
between hosts, I inoculated two newborn mice with 104 PFU of either T1L or 
S370P/Q371E and returned the infected animals to a cage with uninfected  
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Figure IV-7. The GM2-binding site is conserved in T1 clinical isolates of T1 
reovirus. 
Sequence alignment of prototype strain T1L and three T1 reovirus clinical 
isolates reveals that the residues required for functional GM2 engagement 
(Val354, Ser370, and Gln371) are conserved in T1 reovirus strains.  
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Figure IV-8. T1L and S370P/Q371E replicate comparably within a host.  
Newborn C57BL/6 mice were inoculated with 102 PFU of both T1L and 
S370P/Q371E. Eight-days post-inoculation, mice were euthanized, and intestine 
and brain were resected and homogenized. Homogenates were subject to 
plaque assay using L cells, 10-11 plaques per organ per mouse were picked 
randomly and passaged once on L cells. RNA was extracted from these viral 
stocks and subject to Sanger sequencing for the T1 S1 gene.  The number of 
viral isolates from each strain in the (A) brain and (B) intestine per mouse are 
shown. The overall total number of plaques per strain in all mice combined is 
shown in (C). Differences between T1L and S370P/Q371E are not statistically 
significant as determined by ANOVA followed by Bonferroni’s correction for 
multiple tests.  
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littermates. Eight days later, the mice were euthanized, and intestine, heart, and 
brain were excised and homogenized. Viral titer in organ homogenates prepared 
from inoculated and uninoculated mice was quantified by plaque assay. Both 
wildtype and S370P/Q371E viruses were transmitted to uninoculated littermates 
with equivalent efficiency (Figure IV-9), suggesting that GM2 engagement does 
not alter host-to-host transmission, at least in the setting of mice housed in the 
conditions used for this experiment.  
 
Discussion 
The main finding of this study is that wildtype T1L induces more severe 
hydrocephalus in wildtype mice than does the S370P/Q371E mutant virus. 
Concordantly, T1L induces less severe hydrocephalus in GM2-/- mice compared 
to wildtype mice (Figures IV-5 and IV-6). Previous studies of reovirus-induced 
hydrocephalus report cytoplasmic inclusion formation in the ependymal cells and 
choroid plexus and denuding of the ependymal layer (16, 106, 108). Reparative 
processes were reported to be evident including proliferation of astroglia and 
capillaries at sites of ependymal damage 10-12 days post-inoculation. This tissue 
grew into the ventricular cavities and obstructed the flow of cerebrospinal fluid 
(108). The ependymal layer does not regenerate in mammals of any age. 
However, reactive gliosis is sometimes observed to disrupt the existing 
ependymal cells during the damage response (174). Histological evaluation of 
samples from my study support these previous observations (Figure IV-4). 
Reovirus titer 12 days post-inoculation had subsided to levels undetectable by  
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Figure IV-9. GM2 engagement does not appear to alter littermate 
transmission of T1 reovirus to uninoculated littermates.  
In each cage, two newborn C57BL/6 mice were inoculated with 104 PFU of either 
T1L and S370P/Q371E and returned to their naïve littermates. Eight days later, 
mice were euthanized, and intestine, heart, and brain were excised and 
homogenized. Viral titers in organ homogenates from inoculated and 
uninoculated animals were quantified by plaque assay. No significant differences 
were observed between T1L and S370P/Q371E. Data represent 4-6 inoculated 
mice per virus and 18-21 uninoculated littermates.  
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immunohistochemistry. However, histopathological analysis showed a 
disorganized choroid plexus and enhanced cellular density within the ventricle of 
mice inoculated with wildtype virus. This phenotype was less severe in mice 
inoculated with the S370P/Q371E mutant virus. Accordingly, brain samples of 
wildtype mice inoculated with T1L showed enhanced Ki-67 staining (Figure IV-4), 
which is indicative of cellular proliferation. T1 reovirus also induces dilation of the 
lateral ventricles (16, 106, 108). This finding was recapitulated in wildtype mice 
inoculated with T1L, but disease was much less severe in mice inoculated with 
the GM2-binidng mutant and in mice that did not express the GM2 glycan. Taken 
together, these observations indicate that glycan binding is required for 
hydrocephalus caused by T1 reovirus.  
While infection of mice with viruses that differ in the capacity to engage 
GM2 resulted in differences in disease, these viruses only differed modestly in 
viral replication efficiency (Figures IV-1 and IV-2). Titers produced by wildtype 
and mutant virus were comparable in the intestine and heart following peroral 
inoculation. T1L reached higher titers in the brain following peroral inoculation 
compared with the S370P/Q371E mutant. This result, coupled with the finding 
that T1L also reached higher titers in the brain than S370P/Q371E following 
intracranial inoculation, suggest that T1 σ1-GM2 interactions influence replication 
in the brain, but not dissemination to that site. Interestingly, histological analysis 
revealed that T1L spreads more efficiently than does S370P/Q371E to the 
contralateral hemisphere following intracranial inoculation (Figure IV-3). 
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Ideally, I would have inoculated GM2-/- and wildtype mice with T1L to 
determine whether expression of the GM2 glycan influences viral replication 
efficiency in organs targeted by reovirus. Unfortunately, the GM2-/- mice are not 
as healthy as their wildtype counterparts. Following 18 months of breeding (I lost 
many litters during parturition or nursing), I had five knockout pups that were 
used in the hydrocephalus study. Additional mice were not available for use in 
viral infectivity experiments. Nonetheless, these mice were a valuable resource 
and phenocopied results gathered using the S370P/Q371E mutant virus, thereby 
strengthening the overall conclusions of the study.  
Viral titers in the brain were equilibrated at the doses used to assess 
hydrocephalus (Figure IV-2B), yet differences in disease manifestations were 
observed. The brain is comprised of several cell types, and it is possible that 
certain cell types, such as ependymal cells or choroid plexus cells, display 
altered glycan-dependent susceptibility to T1 reovirus. As these cells constitute 
only a small fraction of the total brain tissue, a viral plaque assay would not be 
sufficiently sensitive to detect differences in replication at such discrete sites. 
Differences in infectivity were not observed by immunohistochemistry, but the 
limit of detection of reovirus antigen by this technique is less than that of viral 
plaque assays. Therefore, it would be useful to determine whether explanted 
cultures of ependymal cells, choroid plexus epithelial cells, or both display GM2-
dependent infectivity. Ependymal cells are difficult to cultivate and often do not 
survive for intervals sufficient to allow reovirus infection studies (Chappell and 
Dermody, unpublished). However, an immortalized ependymoma cell line, 
98 
 
XBD1425, is available (175). Additionally, a choroid plexus cell line, Z310, 
polarizes and expresses tight-junction markers (176). It would be informative to 
infect these cells with wildtype T1L and S370P/Q371E to determine whether 
GM2 binding capacity influences infectivity in these biologically relevant cell 
types. If so, it would be useful to establish whether the capacity of T1L to infect 
these cells is altered following neuraminidase treatment or incubation with 
soluble GM2. These studies would enhance a mechanistic understanding of T1 
reovirus-induced hydrocephalus.  
Glycan-binding capacity does not appear to influence viral spread within a 
host. Both T1L and S370P/Q371E spread efficiently from the intestine to sites of 
secondary replication following peroral inoculation with either virus (Figure IV-1). 
Additionally, co-infection experiments (Figure IV-8) suggest that glycan binding 
does not confer an advantage in viral spread. Following co-inoculation with T1L 
and S370P/Q371E both strains reached the brain in equivalent proportion. T1 
reovirus spreads hematogenously, in contrast to T3 reovirus, which disseminates 
via hematogenous and neural routes (12, 177, 178). Proteinaceous receptor 
JAM-A is a key determinant of hematogenous spread (12) (Lai and Dermody, 
unpublished) and, thus, the finding that virus-GM2 interactions do not influence 
dissemination is not surprising and further supports the conclusion that JAM-A 
binding is sufficient for hematogenous dissemination.  
 The GM2-binding site is conserved in four sequenced isolates of T1 
reovirus (Figure IV-7), suggesting that glycan binding confers some type of 
fitness advantage. The co-infection (Figure IV-8) and littermate transmission 
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experiments (Figure IV-9) demonstrate that GM2 engagement does not enhance 
spread within or between newborn mice under the conditions of my experimental 
protocol. It is possible that these conditions do not accurately reflect how reovirus 
is transmitted between hosts in nature. The day 8 time-point was selected 
because T1L produces peak titers at that time point following peroral inoculation. 
It would be informative to investigate early time points after inoculation to 
determine whether GM2-binding capacity enhances host-to-host spread during 
early rounds of viral replication. Such differences might not be evident by day 8 
post-inoculation. Another possibility is that sequence data is available for too few 
strains of T1 reovirus. There are more sequences of T3 reovirus available, and 
analysis of these sequences indicates the presence of polymorphisms in the 
sialic-acid-binding site of T3 σ1 that disrupt glycan binding (7, 24, 179). It is 
possible that evaluation of additional strains of T1 reovirus would demonstrate 
polymorphisms in the GM2 binding-site of T1 σ1. 
 Differences in reovirus-mediated serotype-specific neurologic disease 
segregate with the S1 gene and are thought to be attributable to differences in 
receptor engagement. Results from this study, coupled with previous reports 
(139, 140), support this hypothesis. My findings demonstrate that T1L induces 
more severe hydrocephalus than does S370P/Q371E, which is deficient in 
glycan binding. Additionally, hydrocephalus was less severe following T1L 
infection of mice lacking the GM2 glycan compared with that induced in wildtype 
mice. T3 reoviruses differing only in the capacity to engage sialic acid differ in the 
100 
 
capacity to infect neurons and cause lethal encephalitis (140). Thus, glycan 
binding contributes to reovirus serotype-specific tropism and pathogenesis.  
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CHAPTER V 
 
SUMMARY AND FUTURE DIRECTIONS 
 
Summary 
Viruses must bind to receptors expressed on the host cell-surface to 
initiate an infectious cycle. Consequentially, receptor expression governs the 
susceptibility of cells to viral infection and serves as a key determinant of 
pathogenesis. Viruses commonly engage multiple receptors to facilitate 
productive attachment and entry (1, 2, 4, 7, 11). However, the function of 
individual receptors in tropism and disease is not completely understood. To fill 
this knowledge gap, I designed and conducted experiments to identify a 
carbohydrate receptor for T1 reovirus (Chapter 2), define residues required for 
functional glycan engagement (Chapter 3), and determine the contribution of 
glycan-binding to T1 reovirus disease (Chapter 4). These experiments 
demonstrated that the T1 σ1 head domain interacts with the sialic acid and 
GalNAc moieties of the GM2 glycan. Moreover, reovirus engagement of GM2 is a 
determinant of hydrocephalus severity in neonatal mice.  
 The lack of an in vitro system had hindered studies of T1 reovirus-glycan 
interactions. A cell-culture system had been established for T3 reovirus-sialic 
acid interactions, as MEL cells are susceptible to only sialic-acid-binding T3 
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reovirus strains, whereas L cells support infection by all reovirus strains (7, 24). 
However, T1 reovirus cannot infect MEL cells. My work established a cell-culture 
system in which T1-sialic acid interactions could be evaluated in vitro as infection 
of MEFs by T1 reovirus is sensitive to neuraminidase (Figure II-1). This 
difference in the requirement for sialic acid engagement is likely due to 
differences in the expression of proteinaceous receptor JAM-A, as MEFs express 
less JAM-A than do L cells (Figure II-2). Levels of JAM-A on the L cell surface 
are likely sufficient to permit efficient attachment in the absence of sialic-acid-
mediated adhesion strengthening.  
 Two independent glycan arrays identified the GM2 glycan as a specific 
sialylated carbohydrate bound by T1 reovirus (Figure II-5). Biological 
confirmation of this array data demonstrated that soluble GM2, but not related 
glycan GM3, blocks T1 reovirus infection of MEFs in a dose-dependent manner 
(Figure II-6). Soluble GM2 also blocks attachment (Figure II-7), suggesting that 
the decreased T1L infectivity in MEFs in the presence of soluble GM2 is the 
result of diminished viral binding to the cell surface. Moreover, soluble GM2 does 
not decrease the capacity of T3 reovirus to infect MEFs, suggesting that GM2 is 
a serotype-specific glycan receptor (Figure II-6C). 
 A combination of crystal structure determination, subsequent structure-
guided mutagenesis, and experiments using mutant viruses with substitutions in 
the glycan-binding pocket, demonstrated that the T1 GM2-binding site is located 
within the σ1 head domain (Figures III-1 and III-2). NMR spectroscopy (Figure III-
13) and X-ray crystallography (Figures III-1 and III-2) experiments established 
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that the sialic acid and GalNAc moieties of GM2 interact with T1 σ1. Residues 
Val354, Ser370, and Gln371 are required for σ1-GM2 engagement as V354F, 
S370P, Q371A, and Q371E mutations diminish hemagglutination capacity and 
infectivity of MEFs (Figures III-8 and III-7).  
A S370P/Q371E mutant virus was selected for use in in vivo studies to 
establish the function of GM2 engagement in reovirus disease. This double-
residue mutant virus replicates with wildtype efficiency in L cells (Figure III-9) and 
is neutralized by a T1 σ1 conformation-specific antibody (Figure III-10) yet 
displays impaired hemagglutination capacity and infectivity in MEFs relative to 
T1L. Unlike wildtype T1L, the T1 σ1-S370P/Q371E mutant protein does not 
interact with GM2 in solution as assessed by NMR spectroscopy (Figure III-13). 
Analysis of wildtype T1L and S370P/Q371E viruses in vivo revealed that 
T1 reovirus-GM2 engagement is not required for viral dissemination, at least in 
newborn mice. Following peroral inoculation, both wildtype and mutant viruses 
replicate within the primary site of replication and disseminate with comparable 
efficiency to all organs sampled except the brain (Figure IV-1). The 
S370P/Q371E produces slightly lower viral titers in the brain following peroral 
inoculation. Additionally, S370P/Q371E produces lower titers than T1L in the 
brain following intracranial inoculation, suggesting that the GM2-binding mutant 
displays impaired capacity to replicate at that site (Figure IV-2). When higher 
doses of T1L and S370P/Q371E were delivered intracranially to assess 
hydrocephalus induction, the viruses produced equivalent titers (Figure IV-2), 
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although S370P/Q371E did not disseminate to the contralateral hemisphere as 
efficiently as did T1L (Figure IV-3).  
Most remarkably in my studies, I found that T1 reovirus σ1-GM2 
interactions contribute to serotype-specific disease. Hydrocephalus is more 
severe in wildtype mice inoculated with T1L compared with the disease induced 
in wildtype mice inoculated with S370P/Q371E. T1L also induced more severe 
hydrocephalus in wildtype mice compared with those lacking expression of the 
GM2 glycan, thereby mimicking the phenotype of limited hydrocephalus induced 
by S370P/Q371E in wildtype mice (Figures IV-5 and IV-6). These observations 
provide strong evidence that GM2-binding capacity is a T1 reovirus virulence 
determinant.  
 
Virus-sialic acid interactions 
Like other viruses, reoviruses engage sialyloligosaccharides to facilitate 
attachment and entry. Lessons learned from these experiments enhance our 
understanding of more general principles of virus-sialic acid interactions. Virus-
sialic-acid binding was thought to rely mainly on the linkage type of the sialic 
acid, but this study and others (48, 53, 180) have recently demonstrated that this 
paradigm is overly simplistic. T3 reovirus binds α2,3-, α2,6-, and α2,8-linked 
sialic acid (9). However, while the GM2 glycan contains an α2,3-linked sialic acid, 
it does not diminish T3 infectivity in MEFs (Figure II-6) and was not identified on 
the glycan array as a potential ligand for T3 σ1 (Reiter, Stehle, Liu, and Feizi, 
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unpublished). Instead, the GM3 glycan was identified as a potential T3 σ1 ligand 
by glycan array. While preliminary experiments (data not shown) suggest that the 
GM3 glycan diminishes T3 infectivity on some cell types, this glycan did exhibit a 
dose-dependent decrease in T1 infectivity (Figure II-6). This finding is similar to 
observations made in studies of polyomaviruses, as BKPyV binds GD3, while 
SV40 binds GM1 (51), both of which contain α2,3-linked sialic acid. In this same 
vein, glycan array screening of seasonal H3N2 influenza virus strains did not 
identify a single moiety that bound all 45 strains tested (53). Moreover, the 
preference of the H3N2 influenza viruses for certain ligands appears to have 
changed over time. Binding preferenecs could be divided into six phases. 
Isolates from the late 1960s and early 1970s preferentially bind short and 
branched sialylated glycans, whereas more contemporary strains from the late 
1980s to 2012 preferentially bind sialic acids attached to long polylactosamine 
chains with high avidity (53). Thus, while these human influenza viruses bind 
glycans containing α2,6-linked sialic acid, the sialic acid linkage type is 
insufficient to explain strain-specific binding preferences. 
 This study and others also shed light on the diversity of the molecular and 
structural basis of virus-sialic acid interactions. Studies of adenovirus (36), 
influenza virus (181-183), polyomavirus (51), rotavirus (22), and T1 (10) and T3 
(9) reovirus demonstrate that in general, viruses primarily engage the sialic acid 
moiety using a modest number of contacts. Additional residues confer specificity 
for a given glycan. Mutation of very few residues is sufficient to alter virus-
sialyloligosaccharide engagement (7, 9, 51, 74, 157). However, my study 
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demonstrates that interactions between the backbone of the viral attachment 
protein and the sialylated glycan can dictate virus-glycan biniding, which had not 
been observed previously (27). 
While influenza virus, reovirus, and rotavirus all contain stalk-like 
attachment proteins, they engage glycans in distinct ways. The carbohydrate-
binding site is conserved in all influenza subtypes and located in a shallow 
groove in HA1 (181). The orientation of Neu5Ac and its interactions with HA1 
also are mostly conserved among all influenza virus strains (181-184). The 
glycosidic bond between sialic acid and galactose can be in the cis or trans 
conformation to accommodate different HA molecules (56).  
Rotavirus attachment is mediated by the VP8* domain of the VP4 protein 
on the virion surface. Rotaviruses engage sialylated and non-sialylated glycans 
using the same site in VP8* (22). The crystal structure of rotavirus strain HAL 
1166 VP8* in complex with human blood group antigen A (HBGA A) 
demonstrates that VP8* displays subtle modifications in its binding site that 
render it incapable of binding sialic acid and instead allow binding to HBGA A. 
The change in specificity is due to the insertion of a single amino acid, Asn187, in 
the binding pocket that reorients a neighboring tyrosine, Tyr188, such that its 
side chain would clash with sialic acid. At the same time, the reoriented tyrosine 
can now form hydrophobic contacts with HBGA A (22). As the remaining 
residues in the binding site are largely conserved among sialic acid-binding and 
non-sialic-acid-binding rotaviruses, this analysis demonstrates the substantial 
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effect on glycan specificity of an exceedingly subtle change in the receptor-
binding pocket.  
The reovirus serotypes have evolved distinct glycan-binding regions in the 
attachment proteins depending on viral serotype. The T1 σ1 head domain 
contacts GM2, whereas the body domain of T3 σ1 contacts sialylated glycans. 
This pattern is reminiscent of the glycan-binding properties of polyomaviruses, in 
which gangliosides bind loop structures on the attachment protein VP1. These 
loops are one of the few regions not conserved between strains and in turn 
dictate strain-dependent receptor specificity (51). Thus, it appears that viruses 
can engage similar receptors using similar binding sites as is seen for influenza 
virus, engage disparate glycans using the same site, as is seen for rotavirus, or 
engage different glycans using distinct sites on the attachment protein as is 
observed for reoviruses and polyomaviruses.  
 Glycan-binding capacity can alter viral disease outcome. For example, 
North American strains of Eastern equine encephalitis virus binds heparan 
sulfate unlike other clinical isolates. This virus is neurovirulent in humans and 
mice, yet, causes limited signs of febrile illness in humans. Studies in which the 
heparan sulfate binding site was disrupted revealed that the capacity to engage 
heparan sulfate leads to increased neurologic disease but decreased cytokine 
production and fever (19). This study and others (139, 140) demonstrate that 
sialylated glycan engagement contributes to serotype-specific reovirus disease. 
GM2 is a serotype-specific glycan bound by T1 reovirus σ1. Ablation of T1 
reovirus-GM2 interactions by altering virus or host attenuates hydrocephalus in 
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mice (Figures IV-5 and IV-6). Studies of T3 reoviruses differing in the capacity to 
engage α2,3-, α2,6-, and α2,8-linked sialylated glycans demonstrate that sialic 
acid-binding T3 reoviruses infect neurons more efficiently and cause a more 
robust encephalitis than do non-sialic-acid-binding strains (140). Taken together, 
such studies suggest that glycan-binding is a determinant of serotype-specific 
disease.  
 
Future Directions 
Identify specific glycan receptors for T3 reovirus 
While GM2 is a glycan engaged by T1 reovirus σ1, the precise glycan 
ligands bound by T3 reovirus σ1 are unknown. Glycan array screening identified 
potential glycan receptors of T3 σ1 including GM3, GM1, and GD1a, as well as 
several others (Reiss, Reiter, Stehle, Liu, and Feizi, unpublished). However, the 
biological relevance of these candidate receptors should validated using 
infectivity and cell-binding assays as I did for T1 reovirus. 
 
Reovirus cell-type specific glycans 
A comprehensive understanding of the role of glycan binding in reovirus 
tropism has been hindered by a lack of information about the specific glycans 
present on tissues targeted by reovirus. While we identified the GM2 glycan as a 
biologically relevant attachment mediator for T1 reovirus, tissue-specific 
expression of GM2 and other gangliosides is not well characterized. Analysis of 
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gangliosides was historically done by extracting glycolipids from cell and tissue 
homogenates and analyzing the glycan profile using thin-layer-chromatography 
(185). I attempted to use a GM2-specific antibody for immunohistochemistry 
analysis to determine whether T1 reovirus targets regions of the brain where 
GM2 is expressed. However, this antibody had not been previously used for 
immunohistochemistry, and I worked with the Vanderbilt Shared Pathology 
Resource Core to develop a staining protocol. However, despite several 
attempts, the staining was not specific when tested using wildtype and GM2-/- 
mice, and therefore, this antibody could not be used to assess the relationship 
between GM2 expression and reovirus targeting in the brain (data not shown).  
New approaches are available to define the glycome expressed on 
specific cells and tissues. Mass spectrometry (186), microarray technology (187), 
and shotgun glycomics enable definition of glycan-expression profiles. In shotgun 
glycomics, glycolipids and glycoproteins are extracted from organs, tissues, or 
cells. The identity and composition of these glycans is determined by high 
throughput liquid chromatography (HPLC), and glycans are added to glycan 
arrays in equal concentrations. This approach (188, 189) could provide a 
framework for studying organ- and cell-type-specific glycan utilization by viruses, 
as recently demonstrated for swine influenza virus (189). This technology could 
be applied to the murine brain, and specifically ependymal and choroid plexus 
cells, to establish whether GM2 is a biologically relevant glycan engaged by T1 
reovirus σ1 on those cell types. Such technology also could be used to define the 
glycans specifically engaged by T3 reovirus on neurons. 
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Defining the sufficiency of GM2 engagement in T1 reovirus tissue tropism 
 T1 and T3 reovirus engage sialyloligosaccharides using distinct domains 
of the attachment protein. However, it is not clear whether differential glycan-
binding capacity is sufficient to potentiate serotype-specific reovirus-mediated 
disease. It would be informative to use viruses containing T1 and T3 σ1 with 
reciprocal exchanges of the glycan-binding sites. Specifically, the viruses should 
be on the T1 background to eliminate additional variables and contain a T1 or T3 
S1 gene. The σ1 proteins on these viruses would comprise either the T1-GM2-
binding site, the T3-sialic acid binding site, both the T1 and T3 glycan-binding 
sites, or neither binding site (Figure V-1). The capacity of soluble GM2 and GM3 
to block infection of MEFs by these viruses as well as their capacity to 
agglutinate human and bovine erythrocytes could be used as in vitro correlates of 
serotype-specific glycan utilization. I propose that such viruses should be 
inoculated intracranially into newborn mice to assess hydrocephalus and 
encephalitis induction. If glycan-binding capacity is sufficient to induce serotype-
specific tropism and disease, then viruses containing the GM2-binding site will 
cause hydrocephalus, irrespective of the rest of the S1 gene. Conversely, viruses 
containing a T3-sialic acid-binding site would have the capacity to infect neurons 
and cause encephalitis. 
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Figure V-1. Schematic of glycan-binding site chimeric σ1 proteins for 
studies of glycan utilization. Parent T1 (red) and T3 (blue) σ1 proteins 
(shaded) can be engineered on an otherwise T1 reovirus background to (i) lack 
binding to all glycan receptors (T1-Δ1, such as S370P/Q371E and T3-Δ3), (ii) 
lack binding to the parent receptor but gain binding to the glycan receptor of the 
heterologous serotype (T1-Δ1+3 and T3-Δ3+1), and (iii) bind both the T1 (GM2) 
and T3 glycans (T1+3 and T3+1). Glycan-binding domains are shown in yellow, 
ablated glycan-binding domains are shaded. (Figure adapted from Sutherland 
and Dermody, unpublished).  
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Understanding the contribution of other reovirus receptors to hydrocephalus 
While wildtype mice infected with S370P/Q371E and GM2-/- mice infected 
with T1L developed less severe hydrocephalus than did wildtype mice (Figure IV-
5), all mice developed some disease compared with control mice inoculated with 
PBS. This observation suggests that glycan-binding capacity contributes to 
hydrocephalus, but it is not the sole determinant of disease induction. Therefore, 
experiments should be conducted to test whether other known reovirus receptors 
contribute to hydrocephalus in mice. A function for the other known reovirus 
receptors, JAM-A and NgR1, in T1-mediated hydrocephalus has not been 
formally evaluated. It would be informative to inoculate JAM-A-/- and NgR1-/- mice 
with T1L and S370P/Q371E and assess ventricular volume by MRI to determine 
whether these receptors are required for hydrocephalus induction. The precedent 
for multiple receptors contributing to reovirus infection comes from studies of T3 
reovirus infection of cortical neurons in vitro. While JAM-A is dispensable for 
infection of primary neurons in culture (12), fewer wildtype neurons are infected 
following inoculation with a sialic acid-binding mutant compared with wildtype 
virus. Additionally, T3 infectivity is diminished in NgR1-/- neurons compared with 
wildtype neurons and nearly ablated in NgR1-/- neurons infected with a T3 
reovirus that cannot bind sialic acid. Collectively, these findings indicate that both 
NgR1 and sialic acid engagement are required for optimal infection of neurons 
(15). 
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The contribution of reovirus infection to human disease 
Reovirus is infrequently associated with human disease. However, my 
findings raise the possibility that reovirus infection might be associated with 
hydrocephalus in human infants. The causes of congenital hydrocephalus in 
humans are not completely understood, but some prescription drugs (190) and 
viruses (191, 192) are thought to be potential triggers. In support of this 
hypothesis, analysis of brain samples from persons seropositive for mumps 
demonstrated that 65 percent of the mumps-infected brains displayed evidence 
of ependymitis (193). Additionally, a case-control study suggested that prenatal 
infection with cytomegalovirus was more prevalent in infants with hydrocephalus 
compared with healthy controls (191). However this study needs to be repeated 
with a larger sample size to assess statistical significance.  
Most humans are seropositive for reovirus by five years of age (194), but 
the associations of reovirus infection with human disease are not well defined. T3 
reovirus has been isolated from children with febrile and diarrheal illnesses (195). 
Additionally, T1 reovirus has been isolated from the brain of an infant who had 
died from hepatitis and encephalitis (196). However, reovirus strains also have 
been isolated from asymptomatic children (99). Therefore, it is not clear whether 
reovirus causes illness in humans. Viral etiology of disease in humans is difficult 
to definitively demonstrate compared with experimental animals. However, one 
study found that only a few of the twenty-seven healthy, young-adult volunteers 
inoculated with reovirus intranasally developed a mild febrile illness, and it was 
not clear whether reovirus was responsible for the symptoms (197). 
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It is plausible that T1 reovirus, like other viruses (191, 193), might be 
associated with congenital infection and hydrocephalus in humans. In support of 
this idea, T1 reovirus binds human ependymal cells in vitro (105) and causes 
hydrocephalus in newborn mice. It would be worthwhile to perform a case-control 
study of infants born with congenital hydrocephalus and those with no neurologic 
disease. As reovirus does not cause disease in adults, it is likely that the mother 
would be asymptomatic. Additionally, it may be informative to quantify IgG and 
IgM antibody titers in the serum of children with congenital hydrocephalus, 
healthy controls, and their mothers to determine whether reovirus antibody titers 
are higher in cases than controls. If true, this finding would suggest that reovirus 
infection contributes to congenital hydrocephalus in humans.  
 
Therapeutic targeting of virus-sialic acid interactions 
Sialic-acid-binding viruses include important human pathogens, such as 
adenovirus, influenza virus, and rotavirus, as well as viruses with therapeutic 
applications, such as adenovirus and reovirus, which are being tested as gene-
delivery vectors and oncolytics. Therefore, manipulating these virus-sialic acid 
interactions may enhance therapeutic design and efficacy. For example, 
influenza virus attachment and release necessitate interactions with sialic acid 
and are potent antiviral targets. Structure-based therapeutic design led to the 
generation of oseltamivir (Tamiflu®) and zanamivir (Relenza®), which are sialic 
acid derivatives that inhibit influenza virus NA and block release of progeny 
virions(54, 55). Additionally, DAS181 (Fludase®) is a fusion of an epithelial 
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anchoring domain and a sialidase, which removes α2,3- and α2,6-linked sialic 
acid from the respiratory epithelium (198, 199). DAS181 is effective against 
influenza A and B strains in vitro (198), protects mice from lethal challenge with 
H1N1 (198), and protects mice post-exposure from H5N1 (199). Phase II clinical 
trials demonstrated that DAS181 reduced viral shedding in humans (200). Thus, 
both virus and host can provide antiviral targets for disruption of virus-sialic acid 
interactions. Knowledge gained from studies of virus-glycan binding may be 
particularly useful to retarget viruses either for use as gene delivery vehicles or 
oncolytics.  
Reoviruses are naturally cytotoxic and preferentially infect transformed 
cells (201-204). Targeting of transformed cells coupled with the relative 
avirulence of these viruses in humans beyond the first few weeks of life makes 
reovirus an attractive candidate for oncolytic therapy. Phase I-II clinical trials 
have shown that reovirus strain T3 Dearing (Reolysin®) is safe and non-toxic 
even at high doses (142-144). T3 Dearing is now being tested in phase III clinical 
trials for the treatment of head and neck cancer (205).  
It is not yet clear why reoviruses infect tumor cells more efficiently than 
untransformed cells, but it is possible that distribution, accessibility, and density 
of cellular receptors contribute to this process. Interestingly, the sialylation 
pattern in transformed cells is altered compared with that in untransformed cells 
(149). The abundance of sialic acid is increased in transformed cells owing to 
overexpression of sialyltransferases (145). Understanding reovirus-glycan 
interactions could improve tumor targeting. In this regard, a T3 Dearing virus 
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lacking the σ1 head domain is less toxic in the host yet retains its oncolytic 
potential (206). This truncated T3 reovirus cannot bind JAM-A, indicating that the 
virus must adhere to cells using only sialic acid or a receptor that has not been 
identified. It is possible that the altered glycan profile of cancer cells allows all 
three sialic-acid-binding sites of the T3 σ1 trimer to be occupied, thereby 
enhancing the avidity through the multivalency of the virus. In support of this 
idea, human glioblastoma cells grown in standard culture conditions require JAM-
A binding for reovirus infection, but in spheroid cultures of these glioblastoma 
cells, which more closely resemble tumors in humans, reovirus infection is 
independent of JAM-A expression (207), suggesting that other factors, such as 
sialylated glycans, mediate attachment of reovirus to tumor cells.  
Structural studies of reovirus σ1-sialic acid interactions (9, 10) coupled 
with structure-guided mutagenesis (41, 151) can facilitate the generation of 
strains with increased affinity for sialic acids that may have enhanced tumor 
specificity and oncolytic potential. Some tumor cells overexpress gangliosides 
such as GM2 (145, 149). Humanized antibodies directed against GM2 prevent 
the formation of organ metastases in mice with small-cell lung cancer (150). It is 
possible that ganglioside overexpression in tumor cells alters the susceptibility of 
certain cancers to reovirus infection. T1 reovirus has not been tested for oncolytic 
capacity, but these observations about glycan expression on tumors provide 
sufficient rationale to initiate such experiments. Another possible approach would 
be to engineer an oncolytic T3 reovirus that contains the T1-GM2-binding site. 
Such a virus might have enhanced targeting to GM2-expressing tumor cells. 
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Thus, understanding the molecular basis of reovirus-glycan interactions might 
improve the design of effective oncolytics. 
 
Conclusions 
Work presented in this thesis enhances an understanding of the molecular 
basis of T1 σ1-carbohydrate interactions, defines the function of GM2 
engagement in T1 reovirus-mediated hydrocephalus, and illuminates more 
general principles of virus-glycan interactions. Yet, perhaps the greatest 
contribution to the field comes in new questions raised by this research. Using 
knowledge gained from these studies, it is now possible to elucidate the function 
of glycan binding in reovirus serotype-specific neurologic disease and determine 
how multiple reovirus attachment mediators work in concert to infect cells within 
the CNS. Additionally, as glycomics technology continues to improve, it will be 
fascinating to define cell- and tissue-specific glycan utilization by T1 reovirus and 
other viruses to establish how intricate glycan-binding preferences displayed by 
viruses function in tropism and pathogenesis. Reovirus also is being evaluated in 
clinical trials as an adjunct to conventional chemotherapy for the treatment of 
cancer. Since certain cancer cells display altered glycan profiles (145), it is 
possible that manipulation of reovirus-glycan engagement will enhance 
therapeutic efficacy.  
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CHAPTER VI 
 
MATERIALS AND METHODS 
 
Cells 
Spinner adapted murine L cells were grown in suspension culture in 
Joklik's minimum essential medium (Lonza) supplemented to contain 5% fetal 
bovine serum (FBS) (Gibco), 2 mM L-glutamine, 100 U/mL penicillin, 100 µg/mL 
streptomycin (Invitrogen), and 25 ng/mL amphotericin B (Sigma-Aldrich). MEFs 
were generated from C57/BL6 mice at embryonic day 13.5 as described (113, 
208). MEFs were maintained in Dulbecco’s modified Eagle’s minimum essential 
medium (DMEM) (Gibco) supplemented to contain 10% FBS, 2 mM L-glutamine, 
100 U/ml penicillin, 100 μg/mL streptomycin, 1X MEM nonessential amino acids 
(Sigma-Aldrich), 20 mM HEPES, and 0.1 mM 2-mercaptoethanol (Sigma-
Aldrich). Cells at passages 3-6 were used in this study. HeLa S3 cells were 
maintained in DMEM supplemented to contain 10% FBS, 2mM L-glutamine, 100 
U/mL penicillin, 100 μg/ml streptomycin, and 25 ng/mL amphotericin B.  
 
Viruses and Plasmid-Based Reovirus Rescue 
Viruses were generated using plasmid-based reverse genetics (41, 151). 
BHK-T7 cells (5 x 105) were seeded in 60 mm tissue-culture dishes (Corning) 
and allowed to incubate at 37°C overnight. OptiMEM (Invitrogen) (0.75 ml) was 
mixed with 53.25 μl TransIT-LT1 transfection reagent (Mirus) and incubated at RT 
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for 20 min. Plasmid constructs representing cloned gene segments from the T1L 
genome, pT7S1 T1L, pT7S2 T1L, pT7L3S3 T1L, pT7S4 T1L, pT7M1 T1L, 
pT7L1M2 T1L, and pT7L2M3 T1L were mixed into the OptiMEM/TransIT-LT 
solution. Equal amounts of each plasmid were added for a total of 17.75 μg DNA. 
The plasmid-transfection solution was added to BHK-T7 cells and incubated for 
3-5 days. Following two freeze-thaw cycles, recombinant viruses were isolated 
by plaque purification using L-cell monolayers (117). Purified virions were 
generated using second-passage L cell-lysate stocks. Viral particles were vertrel-
extracted from infected cell lysates and layered onto 1.2 to 1.4 g/cm3 CsCl 
gradients and centrifuged at 62,000 x g for 18 h. Bands were collected and 
dialyzed exhaustively in virion-storage buffer as described (178, 209). To 
generate mutant viruses, resides V354, S370, Q371, and M372 in the S1 gene 
plasmid were altered by QuickChange (Stratagene) site-directed mutagenesis. 
S1 gene sequences were confirmed using the OneStep RTPCR kit (Qiagen), 
gene-specific primers, and viral dsRNA extracted from infected L cells (Trizol, 
Invitrogen). Primer sequences are provided in Table VI-1. Sanger sequencing 
was performed using purified PCR products (Gene Hunter and Vanderbilt 
Sequencing Core). Genotypes were confirmed by electrophoresis of viral 
particles in 4-to-20% gradient sodium dodecyl sulfate polyacrylamide gels 
stained with ethidium bromide and visualized by UV illumination(210). Particle 
concentrations were determined using the conversion 1 AU260 = 2.1 x 10
12 
particles (117). Viral titers were quantified by plaque assay(117) or fluorescent 
focus assay (11). 
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Table VI-1. Primers used in these studies. The sequences of the primers used 
for wildtype and mutant virus generation and sequencing are shown.  
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Antibodies 
Polyclonal immunoglobulin G (IgG) raised against T1L and T3D was used 
to stain for reovirus antigen (211). Alexa-488 conjugated goat anti-rabbit antibody 
(Invitrogen) was used as a secondary antibody. Monoclonal rat anti-mouse JAM-
A (Abcam, clone H202-106) was used to stain for JAM-A expression followed by 
goat anti-rat secondary antibody conjugated to Alexa-488 (Invitrogen). 
Conformation-sensitive neutralizing mAb 5C6 specific for T1L (155) was used in 
neutralization assays as described (212). Ki-67 (Vanderbilt University Histology 
Core) was used as a marker for cell proliferation. Anti-caspase 3 (Vanderbilt 
University Histology Core) was used as a marker for apoptosis. Polyclonal rabbit 
ganglioside GM2-specific antiserum (EMD Millipore) was used to stain for GM2. 
 
Infectivity Studies 
L cells (105) or MEFs (5 x 104) were incubated in 24-well plates (Costar) at 
37°C overnight. To evaluate the importance of sialic acid engagement in T1L 
infection, cell monolayers were treated with 100 mU/ml of A. ureafaciens 
neuraminidase diluted in PBS (MP Biomedicals, LLC) or PBS alone (mock) at RT 
for 1 h prior to virus adsorption at an MOI of 1 PFU/cell in L cells or 100 PFU/cell 
(as titered in L cells) in MEFs. Following incubation at RT for 1 h, the inoculum 
was removed, and cells were washed twice with PBS and incubated at 37°C for 
20 h. Cells were fixed in methanol and visualized by indirect immunofluorescence 
(11) with the addition of a DAPI stain to quantify cell nuclei. Cells were blocked in 
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PBS supplemented to contain 5% bovine serum albumin (BSA) (Sigma). Infected 
cells were detected by staining with reovirus polyclonal antiserum diluted 1:1000 
and secondary Alexa-488 goat anti-rabbit Ig 1:1000 (Invitrogen). Nuclei were 
quantified using DAPI (1:1000). All antibodies were diluted in PBS supplemented 
to contain 0.5% Triton X-100. Infectivity studies were performed in triplicate wells. 
Three fields of view per well were quantified using the Axiovert 200 fluorescence 
microscope (Carl Zeiss).  
To determine the effect of soluble lectins on viral infectivity, cells were 
incubated with 10 μg/ml of Sambucs nigra, Maackia Amurensis, or Aleuria 
Aurantia lectins (Vector Labs) at room temperature for 1 h. Excess lectins were 
removed, and virus was adsorbed to MEFs (MOI of 100 PFU/cell as titered on L 
cells) at room temperature for 1 h. Cells were washed twice, and infectivity was 
determined by indirect immunofluorescence.  
To determine the effect of soluble glycans on infectivity, virus was 
incubated with 5mM 3’SL (Carbosynth and Sigma Aldrich) or various 
concentrations of GM2 or GM3 glycan (Elicityl) at room temperature for 1 h. The 
virus-glycan mixture was adsorbed to MEFs (MOI of 100 PFU/cell as titered on L 
cells) at room temperature for 1 h. Cells were washed twice, and infectivity was 
determined by indirect immunofluorescence.  
 
JAM-A Expression 
To determine the relative amount of JAM-A on L cells and MEFs, 5 x 105 
cells were stained with rat anti-mouse JAM-A at a dilution of 1:200 followed by 
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staining with Alexa-488 labeled goat anti-rat Ig at 1:1000. All staining was done in 
PBS supplemented to contain 2% FBS. Fluorescence was quantified using an 
LSRII (BD, Vanderbilt University Flow Cytometry Shared Resource). Mean 
fluorescence intensity of a forward and side scatter gated population was 
determined using FlowJo software (Treestar).  
 
T1L σ1 Protein Expression and Purification 
Construct σ1long comprises the three most C-terminal predicted β-spirals of 
T1L σ1 and the head domain (amino acids 261-470). Construct σ1short comprises 
the most C-terminal predicted β-spiral of T1L σ1 and the head domain (amino 
acids 300-470). Expression and purification of T1L σ1long and T1L σ1short were 
facilitated by attaching a trimeric version of the GCN4 leucine zipper (10) to the 
N-terminus of the σ1 sequence, similar to the strategy we used to express T3D 
σ1 (9). The σ1 construct was cloned into the pQE-80L expression vector 
(Qiagen), which includes a non-cleavable N-terminal His6-tag. The protein was 
expressed in E. coli Rosetta 2 (DE3) (Novagen) by autoinduction at 20°C for 48 
to 72 h. Bacteria were lysed using an EmulsiFlex (Avestin) homogenizer and 
purified via Ni-affinity chromatography (His-Trap FF column, GE Healthcare). 
chromatography (His-Trap FF column, GE Healthcare). The fusion protein was 
eluted from the column, and the protein solution was desalted using a PD10 
desalting column (GE Healthcare). The GCN4 domain and the His6-tag were 
removed from the fusion protein using 1 μg trypsin per mg protein at 20°C for 4 h. 
124 
 
The resultant products were subjected to size-exclusion chromatography 
(Superdex 200) to remove the tags, trypsin, and other minor impurities. 
Undigested versions of both constructs were used for glycan array screening. 
STD NMR experiments were performed using σ1long. Both constructs were used 
for structural analysis. Uncleaved σ1short yielded crystals diffracting to 2.6 Å 
resolution. This higher resolution structure was used as a reference model for 
refinement of the lower-resolution structures of cleaved σ1long in complex with the 
GM2 glycan. 
 
Glycan Microarray Analyses 
Microarrays were composed of lipid-linked oligosaccharide probes, 
neoglycolipids (NGLs) and glycolipids, robotically printed on nitrocellulose-coated 
glass slides at 2 and 7 fmol per spot using a non-contact instrument, and 
analyses were performed as described (10). T1L σ1long, was used in the first 
glycan array comprising 124 oligosaccharide probes (5 non-sialylated and 119 
sialylated, Glycosciences Array Set 40-41), at 5 fmol per spot T1L σ1short, was 
used on the second array, designed in the Feizi laboratory (in house designation 
Ganglioside Dose Response Array set 1) comprising 21 ganglioside-related 
probes each arrayed at four levels: 0.3, 0.8, 1.7 and 5.0 fmol/spot. 
For the initial analysis of His-tagged T1L σ1long, the protein was incubated with 
mouse monoclonal anti-poly-histidine (Ab1) and biotinylated anti-mouse IgG 
antibodies (Ab2) (both antibodies from Sigma) at a ratio of 4:2:1 (by weight). The 
σ1long-antibody complexes were prepared by preincubating Ab1 with Ab2 at 
125 
 
ambient temperature for 15 min, followed by addition of His-tagged T1L σ1long 
and incubation on ice for 15 min. The σ1long-antibody complexes were diluted in 5 
mM HEPES (pH 7.4), 150 mM NaCl, 0.3% (v/v) Blocker Casein (Pierce), 0.3% 
(w/v) bovine serum albumin (Sigma), 5 mM CaCl2 and 40 mM imidazole (referred 
to as HBS-Casein/BSA-imidazole), to provide a final σ1long concentration of 150 
μg/ml, and overlaid onto the arrays at 20 °C for 2 h. Binding was detected using 
Alexa Fluor 647-labeled streptavidin (Molecular Probes) at 1 μg/ml. Microarray 
data analyses and presentation were facilitated using dedicated software as 
described (10). 
For the analyses of His-tagged T1L σ1short, different assay conditions were 
evaluated with and without complexation (not shown). The condition selected as 
optimal was without precomplexation. His-tagged σ1short was diluted in HBS-
Casein/BSA-imidazole, overlaid at 300 μg/ml, followed by incubation with Ab1 
and Ab2 (each at 10 mg/ml, precomplexed at ambient temperature for 15 min). 
Binding was detected using Alexa Fluor 647-labeled streptavidin.  
 
Crystallization, X-Ray Structure Determination, and Refinement 
Crystals of uncleaved σ1short formed in 0.1 M MES/imidazole (pH 6.5), 
10% PEG 4000, 20 % glycerol, 0.02 M sodium formate, 0.02 M ammonium 
acetate, 0.02 M trisodium citrate, 0.02 M sodium potassium L-tartrate, 0.02 M 
sodium oxamate at 4°C using the sitting-drop-vapor-diffusion method. No 
additional cryoprotection was necessary. Crystals of σ1long formed in 0.1 M Na 
cacodylate (pH 6.0-6.6), 1.2-1.5 M (NH4)2SO4 at 4°C using the sitting-drop-vapor-
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diffusion method. For preparation of complexes, these crystals were transferred 
to 20 mM GM2 (Elicityl) for soaking in the crystallization solution for 5-10 min. 
Prior to flash-freezing, the crystals were transferred to a solution containing 0.1 M 
Na cacodylate, 1.34 M (NH4)2SO4, 25% glycerol, and 20 mM GM2 or GM3 
glycan.  
The crystals belonged to space group P3221 and contained one trimer in 
the asymmetric unit. A complete data set was collected at the Swiss Light 
Source, beamline X06SA. XDS was used to index and scale the reflection data. 
The structure was determined by molecular replacement with Phaser (CCP4) 
using the coordinates of T1L σ1 derived from the previously determined T1L σ1-
JAM-A complex structure as a search model (130). Manual model building was 
carried out using coot. Structural refinement was performed using Refmac5 
(CCP4), Phenix, and autoBUSTER. 
Refinement of the ligands was performed using the CCP4 library and 
user-defined constraints. Structure images were created using PyMOL. 
Coordinates and structure factors of the complex have been deposited in the 
Protein Data Bank by Dr. Thilo Stehle with accession code 4GU3 (T1L-σ1-GM2 
glycan complex). 
 
Sequence and Structural Analysis 
Sequence alignments were performed using T-Coffee and analyzed using 
Jalview (10). Structure alignments were calculated by secondary-structure 
matching (SSM) superposition in coot. The Ramachandran plot was generated 
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with Rampage (CCP4). Buried surface areas were calculated using AreaImol 
(CCP4) (10). Sequence analysis of available reovirus strains were aligned using 
CLC sequence viewer.  
 
Viral Replication Assays 
Confluent monolayers of L cells in 24-well plates (Corning) were adsorbed 
in triplicate with the various reovirus strains at room temperature for 1 h in PBS. 
Cells were washed twice with PBS, fresh medium was added, and cells were 
incubated at 37°C for various intervals. Cells were frozen and thawed twice prior 
to quantification of viral titer by plaque assay using L cells (117). Viral yield was 
calculated using the formula Log10yieldtx= log10 (PFU/mL)tx- log10 (PFU/mL)0, 
where t is the time post-inoculation.  
 
Conformation-Specific Antibody Neutralization 
The capacity of T1 σ1 conformation-specific antibody to block wildtype 
and mutant virus infectivity was assessed by incubating virus strains with 10 
μg/ml of 5C6 or an mouse IgG2α isotype control at room temperature for 1 h 
prior to adsorption onto L929 cells seeded in confluent monolayers in 24-well 
plates (Corning). Cells were inoculated with the virus antibody mixture at room 
temperature for 1 h. Cells were washed twice with PBS and fresh medium added. 
After incubation at 37°C for 20 h, cells were fixed and infectivity determined by 
indirect immunofluorescence (Figure III-6) or flow cytometry (Figure III-10).  
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Hemagglutination Assay 
Purified reovirus virions (1011 particles) were distributed into 96-well U-
bottom microtiter plates (Costar) and serially diluted twofold in 0.05 ml of PBS. 
Human type O erythrocytes (Vanderbilt University Blood Bank) were washed 
twice with PBS and resuspended at a concentration of 1% (vol/vol). In some 
assays, erythrocytes were treated with PBS or A. ureafaciens neuraminidase 
(MP Biomedicals, LLC) at room temperature for 1 h prior to virus adsorption. 
Erythrocytes (0.05 ml) were added to wells containing virus particles and 
incubated at 4°C for 3 h. A partial or complete shield of erythrocytes on the well 
bottom was interpreted as a positive HA result; a smooth, round button of 
erythrocytes was interpreted as a negative result. HA titer is expressed as 1011 
particles divided by the number of particles/HA unit. One HA unit equals the 
number of particles sufficient to produce HA.  
 
Hemagglutination Inhibition Assay 
Human erythrocytes were treated with A. ureafaciens neuraminidase at 
room temperature for 1 h, incubated with 4 HA units of various virus strains, 
incubated at 4°C for 3 h, and scored for agglutination.  
 
STD NMR Spectroscopy 
NMR spectra were recorded using 3 mm tubes and a Bruker AVIII-600 
spectrometer equipped with a room temperature probe head at 283 K and 
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processed with TOPSPIN 3.0 (Bruker). Samples containing 2 mM GM2 glycan 
(Elicityl), 20 mM potassium phosphate (pH 7.4), and 150 mM NaCl with and 
without 16.8 μM of T1L σ1 or the mutant proteins were used for the STD NMR 
measurements and the frequency control, respectively. Samples were prepared 
in D2O, and no additional water suppression was used to preserve the anomeric 
proton signals. The sample without protein also was used for spectral 
assignment. The off- and on-resonance irradiation frequencies were set to -30 
ppm and 7.3 ppm, respectively. The irradiation power of the selective pulses was 
57 Hz, the saturation time was 2 s, and the total relaxation delay was 3 s. A 50 
ms continuous-wave spin-lock pulse with a strength of 3.2 kHz was employed to 
suppress residual protein signals. Spectra were multiplied with a Gaussian 
window function prior to Fourier transformation. Spectra were referenced using 
HDO as an internal standard as described (10). 
 
Virus Attachment by Flow Cytometry 
MEFs were adsorbed with reovirus strains at 4°C for 1 h to prevent 
internalization. Cells were washed twice in PBS and stained with Alexa-647 
labeled reovirus antiserum. Labeling was performed using the AlexaFluor® 
Antibody Labeling kit (Molecular Probes) according to manufacturer’s 
instructions. The percentage of cells bound by virus was quantified using an 
LSR-II flow cytometer (Vanderbilt Flow Cytometry Core). Analysis was performed 
using FlowJo software (Tree Star).  
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Infection of Mice 
C57Bl/6 mice were obtained from the Jackson Laboratory to establish a 
breeding colony at Vanderbilt University. The GM2-/- mice lack functional copies 
of galgt1 and galgt2. These mice are on a C57Bl/6 background and were 
provided by Dr. Dapeng Zhou (MD Anderson Cancer Center). Two-to-three day 
old mice were inoculated perorally or intracranially with reovirus diluted in PBS. 
For co-infection experiments, strains were mixed and inoculated into mice. 
Peroral inoculations (50 μL) were administered using a Hamilton syringe, 30-
gauge needle, and Intramedic PE-10 polyethylene tubing (BD Biosciences) (12). 
Intracranial inoculations (5 μL) were delivered into the right cerebral hemisphere 
using a Hamilton syringe and 30-gauge needle. For analysis of viral replication, 
mice were euthanized at various intervals post-inoculation, organs were excised, 
collected in 1 mL of PBS, frozen and thawed twice prior to homogenization using 
a TissueLyser (Qiagen). Viral titer was quantified by plaque assay using L929 
cells.  
 For littermate transmission studies, two two-to-three day old pups were 
inoculated perorally with either T1L or S370P/Q371E and placed into cages with 
6-8 uninoculated littermates. Eight days post-inoculation, inoculated and 
uninoculated mice were euthanized, and viral titers in organs targeted by reovirus 
were quantified by plaque assay.  
 For immunohistochemical and pathology analysis, mice were euthanized 
at various intervals following inoculation, and organs were excised and fixed 
overnight in 10% formalin. Fixed organs were paraffin-embedded, and 6 μM 
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sections were prepared (Vanderbilt University Translational Pathology Shared 
Resource). Sections were evaluated for histological damage following 
hematoxylin and eosin staining. Reovirus proteins were detected using polyclonal 
reovirus antisera. Proliferation, apoptosis, and ganglioside GM2 were detected 
using Ki-67-, caspase-3-, and GM2-spcecific antibodies, respectively.  
All animal husbandry and experimental procedures were performed in 
accordance with Public Health Service policy and approved by the Vanderbilt 
University School of Medicine Institutional Animal Care and Use Committee. 
Unless otherwise stated in the appendices, all animal work presented in in this 
thesis was performed under Terence Dermody’s animal protocol M/05/198.  
 
Magnetic Resonance Imaging 
Mice were inoculated with 108 PFU of wildtype and mutant reovirus 
strains. Twenty-one days post-inoculation, mice were anesthetized via inhalation 
of 2%/98% isoflurane/oxygen. Animals were secured in a prone position with the 
head placed in a 25-mm inner diameter radiofrequency (RF) coil. A rigid bite-bar 
and head restraint were used to ensure proper positioning and reduce motion-
induced artifacts. Animals were placed in a Varian 7T horizontal bore magnetic 
resonance imaging system (Varian Inc, Palo Alto, CA) to collect imaging data. 
Respiration rate and internal body temperature were continuously monitored. A 
constant body temperature of 37 C was maintained using heated air flow. 
For each animal, multi-slice scout images were collected in all three 
imaging planes (axial, sagittal, and coronal) using a gradient echo sequence with 
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repetition time (TR) = 75ms, echo time (TE) = 5ms, slice thickness = 2mm, and 
flip angle = 35 . An average of four acquisitions was obtained for each animal. 
Additional parameters include field of view (FOV) = 50mm x 50mm and data 
matrix = 128 x 128. 
Following localization of the brain, T2-weighted fast-spin echo images 
were collected over 12-20 imaging slices for all three imaging planes (axial, 
coronal, and sagittal), with FOV = 20mm x 20mm, slice thickness = 0.75mm, and 
data matrix = 128 x 128. Additional parameters include TR = 5 seconds, echo 
train length = 16, echo spacing = 8ms, TE = 64ms, and number of experiments = 
10. 
 
Ventricular Quantification 
Ventricle volume measurements were performed using Matlab 2013a (The 
MathWorks, Inc, Natick, MA). A region of interest encompassing the entire brain 
was manually drawn for each slice, and a signal intensity threshold 1.25 times 
the mean signal intensity in a manually drawn region of cortical gray matter was 
used to segment voxels within the ROI corresponding to ventricle/cerebrospinal 
fluid. The total ventricular volume was calculated as the sum of the number of 
voxels within the segmented ventricle region multiplied by the volume of each 
voxel. The appearance of both eyes in the plane of analysis was used as a 
marker to standardize regions for ventricular volume quantification. Following the 
appearance of both eyes, used as a landmark, one slice was skipped and the 
next 8 slices quantified.  
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Statistical Analysis 
Statistical analyses were performed using Prism (Graphpad). P values of 
less than 0.05 were considered to be statistically significant. Descriptions of the 
specific tests are found in the figure legends. Viral replication assays, 
hemagglutination assays, infectivity assays comprising more than two virus 
strains, and animal studies were analyzed by ANOVA followed by a Bonferroni’s 
correction for multiple tests. Student’s t tests were used for analysis of infectivity 
and binding experiments where only two strains were compared.  
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APPENDIX 1 
 
REOVIRUS INFECTION ABROGATES ORAL TOLERANCE IN MICE 
 
Introduction 
Celiac disease is characterized by a loss of tolerance to dietary gluten 
peptides found in wheat, barley, and rye, resulting in a robust inflammatory 
response in the small intestine. Celiac disease manifests as varying degrees of 
small intestinal injury, ranging from increased intestinal epithelial leukocyte 
infiltration to total villous atrophy (213-215). The pathogenesis of celiac disease 
displays characteristics of both allergic and autoimmune conditions, as 
individuals with this disorder have gluten-specific antibodies and CD4+ T cells 
(216) as well as auto-antibodies directed against tissue transglutaminase 2 (TG2) 
(216).  
The risk of developing celiac disease is higher in persons who have a 
sibling, especially a monozygotic twin, with the disease, indicating that there is a 
strong genetic component (217). Genome-wide-association-studies (GWAS) 
identified genes associated with inflammatory cytokines, antigen presentation, 
NF-κB, and T cell and NK cell activation as risk factors for developing celiac 
disease (218, 219). Human major histocompatibility complex (MHC) genes, 
specifically those encoding human leukocyte antigens (HLA)-DQ2 and DQ8 
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molecules, also are associated with an increased risk of celiac disease 
development. Remarkably, these alleles are expressed in more than 99 percent 
of persons with celiac disease (219). HLA-DQ2 and DQ8 molecules present 
(220-223) gluten peptides to potentiate generation of gluten-specific CD4+ T 
cells. The high proline content of gluten renders it difficult to digest. Upon 
reaching the intestine, long gluten peptides serve as substrates for TG2, which 
preferentially recognizes proteins, such as gluten, that contain a Gln-X-Pro motif. 
TG2 postranslationally modifies the glutamine residues to glutamate (220-224). 
These negatively charged, deamidated gluten peptides interact with the positively 
charged pockets in the HLA-DQ2 and DQ8 molecules (225-227), thereby 
increasing binding affinity, enhancing peptide-MHC complex stability, and 
promoting gluten-specific CD4+ T cell generation (228). Deamindation enhances 
the interaction of gluten with these HLA molecules, but the T-cell receptor (TCR) 
does not have a preference for the native or deamidated form of the gluten 
peptide (229). Furthermore, gluten-specific CD4+ T cells may recognize B cells 
presenting gluten-TG2 complexes and thereby provide help to B cells to generate 
TG2-specific autoantibodies (230). Taken together, these findings suggest that 
the MHC risk alleles have a functional role in celiac disease progression. 
However, these molecules also are found in persons without celiac disease, 
indicating that these alleles are by no means sufficient to induce the illness (231). 
It is possible that enteric viral infections enhance the risk of celiac disease 
onset in persons with HLA-DQ2 or DQ8 alleles. Epidemiological studies have 
linked rotavirus infections with celiac disease in genetically susceptible 
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individuals (232). Astroviruses have been isolated from some individuals at the 
onset of celiac disease but were not found in persons presenting with diarrhea 
that was unrelated to celiac disease (233). Finally, adenovirus type 12 antibodies 
are more prevalent in individuals with celiac disease compared with healthy 
controls (234). Thus, it appears that some enteric viruses may trigger celiac 
disease, in a subset of individuals. 
Enteric viral infections may alter the cytokine profile in the gut and 
consequentially alter the immune response to dietary antigens. Type 1 
interferons (IFNs) released in response to viral infection may potentiate the loss 
of tolerance to gluten in humans. In support of this idea, IFNα levels are elevated 
relative to controls in the mucosa of some individuals with celiac disease (235) 
(Jabri, unpublished). Moreover, IFNα treatment of hepatitis C virus infection leads 
to celiac disease in some persons (236). Peroral administration of IFNβ to mice 
results in increased lymphocyte production of inflammatory cytokine IFNγ (237), 
which is a hallmark of loss of oral tolerance.  
Oral tolerance is a term used to describe systemic immune 
unresponsiveness to previously fed antigen. Understanding mechanisms of oral 
tolerance induction and maintenance will provide insight into the pathogenesis of 
diseases such as celiac disease in which oral tolerance is abrogated. The 
concept of oral tolerance was introduced by Merril Chase in 1946 when he 
showed that peroral administration of contact-sensitizing agent 2-4-
dinitrochlorobenzene does not lead to sensitization as expected, but rather 
protects mice from an inflammatory response upon subsequent challenge (238). 
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In a traditional experimental set up of oral tolerance (an example is provided in 
Figure AI-1), low doses of antigen are administered perorally to mice over time. 
Animals are subsequently challenged subcutaneously with that antigen mixed 
with an adjuvant. Mice that received the oral antigen display reduced T cell 
proliferation and reduced inflammatory cytokine levels (chiefly IFNγ) in response 
to the challenge compared with mice that did not receive the oral antigen (238). 
Additionally, mice that are tolerized do not mount B cell responses to fed antigen 
in contrast to those that first receive the antigen subcutaneously. The 
concomitant peroral administration of ovalbumin (OVA), a common antigen used 
in oral tolerance experiments, and IFNα, leads to an increase in levels of OVA-
specific antibodies (239). Antibody levels in mice that receive IFNα approximate 
those observed in mice that did not receive antigen perorally. This finding 
suggests that type 1 IFN administration abrogates oral tolerance induction in 
mice.  
I hypothesized that enteric viral infection promotes a loss of oral tolerance 
to fed antigen as a consequence of increased type 1 IFN production. I tested the 
capacity of poly (I:C), a dsRNA analog, and mammalian reovirus, an enteric 
pathogen in humans and mice, to alter the immune response to OVA. This 
project was performed in collaboration with the laboratory of Dr. Bana Jabri at the 
University of Chicago. The results section of this chapter encompasses only 
experiments that I designed and conducted. Karl Boehme, a former postdoctoral 
fellow in the Dermody laboratory, engineered the reassortant virus, T3Drv, 
described below. Romain Bouziat, a postdoctoral fellow in the Jabri laboratory,  
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Figure A1-1. Schematic of oral tolerance experimental design. Mice are fed 
ovalbumin (OVA) or PBS vehicle control every other day for 10 days. Mice are 
then primed with a subcutaneous injection of OVA in complete Freund’s adjuvant 
(CFA). Eight days after the Ova/CFA challenge, draining lymph nodes were 
resected, and cells were isolated and restimulated with Ova ex vivo. Cell 
proliferation, IFNγ levels in the draining lymph node, and presence of OVA-
specific antibodies are quantified.  
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performed the quantitative PCR experiment shown in Figure AI-7 after I 
inoculated and harvested the tissue. Collectively, we found that reovirus infection 
of mice alters the immune response to dietary antigen and abrogates tolerance to 
fed OVA. These findings establish a model system for studies to determine how 
viral infection precipitates celiac disease onset in mice, which in turn may 
enhance an understanding of celiac disease pathogenesis in humans.  
 
Results 
Pilot experiments using poly (I:C) 
Initial experiments used poly (I:C), a dsRNA analog, to study the effect of 
TLR signaling on oral tolerance induction and regulatory T cell generation. To 
assess the influence of poly (I:C) on oral tolerance induction, mice were fed OVA 
alone (positive control) or in combination with poly (I:C) every other day for 10 
days. Mice were then primed with a subcutaneous injection of OVA emulsified in 
adjuvant 24 hours after the last feeding. Seven days after this injection, mice 
were euthanized, and the draining lymph nodes were resected, homogenized, 
and restimulated ex vivo with OVA. Mice that received poly (I:C) displayed 
enhanced T cell proliferation as assessed by tritiated thymidine incorporation 
(Figure AI-2A) and increased levels of IFNγ in the draining lymph node following 
OVA-restimulation (Figure AI-2B). In an additional experiment, poly (I:C) 
treatment did not abrogate oral tolerance in IFNαβR-/- mice (Figure AI-3). These  
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Figure AI-2. Poly(I:C) abrogates oral tolerance.  C57Bl/6 mice were fed OVA 
alone or in combination with poly(I:C) every other day for 10 days. Twenty-four 
hours after the last feeding, mice were primed with a subcutaneous injection of 
OVA in complete Freund’s adjuvant (CFA). Eight days post-challenge with 
OVA/CFA, draining lymph nodes were resected, and cells were isolated and 
restimulated with OVA at 37ºC for 48 h. Cell proliferation was quantified by 
tritiated thymidine incorporation (left). IFNγ levels in the draining lymph node 
were quantified by ELISA (left panel). Data shown are from a representative 
experiment of two performed with three mice. Cell proliferation and ELISA assays 
were performed with three technical replicates per mouse. Error bars represent 
standard deviation.  
141 
 
 
 
Figure AI-3. Poly(I:C)-mediated abrogation of oral tolerance is dependent 
on type 1 IFNs.  Wildtype or IFNαβR-/- mice were fed OVA alone or in 
combination with poly(I:C) every other day for 10 days. Twenty four hours after 
the last feeding, mice were primed with a subcutaneous injection of OVA in 
complete Freund’s adjuvant (CFA). Eight days after the OVA/CFA challenge, 
draining lymph nodes were resected, and cells were isolated and restimulated 
with OVA at 37ºC for 48 h. IFNγ levels in the draining lymph node were quantified 
by ELISA. Data are from one experiment performed in triplicate for wildtype mice 
and in duplicate for IFNαβR-/- mice. Error bars represent standard deviation.  
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findings suggest that poly (I:C) stimulates type 1 IFN production, which in turn 
mediates loss of oral tolerance in mice.  
 Oral tolerance is thought to depend on generation of regulatory T cells 
(Tregs) (238, 240). As poly (I:C) treatment abrogated oral tolerance, I 
hypothesized that poly (I:C) inhibits regulatory T cell induction. Naïve CD4+ T 
cells can be induced to form Foxp3+ Tregs following co-culture with dendritic 
cells and treatment with TGFβ and retinoic acid (241). To determine whether poly 
(I:C) prevents Foxp3+ cell induction, I isolated, co-cultured, and treated naïve 
CD4+ T cells and CD11C+ dendritic cells harvested from mouse spleens with 
TGFβ and retinoic acid. After 3 days in co-culture, I quantified the percentage of 
Tregs by flow cytometry. Treatment with poly (I:C) hindered Treg generation in 
vitro (Figure AI-4), suggesting that the poly (I:C) induction of type 1 IFNs impairs 
Treg differentiation and tolerance to fed antigen.  
Reovirus abrogates oral tolerance in mice 
As viruses have been implicated in celiac disease onset in humans (232, 
233), I next sought to assess how enteric viral infection, and not a synthetic 
analog, influences oral tolerance in mice. Following peroral inoculation, 
reoviruses infect the murine alimentary tract, but in adult animals these viruses 
do not disseminate to cause systemic disease (103, 115). Moreover, the reovirus 
serotypes differ in the magnitude of the type 1 IFN response (242-244). While 
infection with either T1 or T3 reovirus leads to IFN production, T1 reovirus 
encodes an IFN antagonist and consequentially produces less type 1 IFN than  
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Figure AI- 4. Poly(I:C) inhibits the induction of regulatory T cells. (A) 
Summary of the experimental protocol. (B) Splenic dendritic cells (DCs) were co-
cultured with naive splenic CD4+Foxp3- T cells at 37ºC for 3 days in the presence 
of TGFβ and retinoic acid (RA) alone or in combination with 0.5 μg/ml or 1 μg/ml 
of poly(I:C). CD4+Foxp3+ regulatory T cell induction was quantified by flow 
cytometry. (C). Graphical representation of the flow cytometry shown in B.  
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does T3D (242, 243). We sought to use T1 and T3 reoviruses to evaluate the 
effect of reovirus infection on oral tolerance induction. However, prototype T3D 
does not efficiently infect the murine intestine, a property that genetically 
segregates with the viral S1 and L2 gene segments (245). Therefore, we 
engineered a T1L/T3D-S1L2 reassortant reovirus, herein referred to at T3Drv, for 
these studies. Following peroral inoculation, T1L and T3Drv produce equivalent 
titers in the intestine, mesenteric lymph node (MLN), and Peyer’s patches (Figure 
AI-5).  
To assess the influence of reovirus infection on oral tolerance induction, 
mice were fed with OVA alone (positive control) or in combination with T1L or 
T3Drv on the first feeding. OVA was administered to the mice perorally every 
other day for four additional feedings. Mice were then primed with a 
subcutaneous injection of OVA emulsified in adjuvant 24 hours after the last 
feeding. Seven days later, mice were euthanized, and the draining, inguinal 
lymph nodes were resected, homogenized, and restimulated with OVA. 
Remarkably, levels of IFNγ in the draining lymph node were higher in mice that 
received OVA in combination with T1L, but not T3Drv, compared with mice that 
received OVA alone (Figure AI-6). This finding demonstrates that infection with 
certain reovirus strains diminishes the induction of tolerance to orally fed 
antigens. 
 Surprisingly, while T3D induces higher levels of type 1 IFNs than does 
T1L in vitro (242, 243), both viruses produced comparable levels of type 1 IFN in 
the Peyer’s patches. However, infection with T1L led to increased type 1 IFN  
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Figure AI-5. T1L and T3Drv produce comparable titers in the intestine.  
C57BL/6 mice at 6-8 weeks of age were inoculated with 1010 PFU of either T1L 
or T3Drv. At days 1 (A), 2 (B), and 4 (C) post-inoculation, mice were euthanized, 
and the intestine, Peyer’s patches, and mesenteric lymph nodes (MLN) were 
excised and homogenized.  Viral titers in tissue homogenates were determined 
by plaque assay. Results are expressed as mean viral titers for 3 mice per virus 
strain per time point. Error bars represent standard deviation. Differences are not 
significant by one-way ANOVA followed by Bonferroni’s correction for multiple 
tests.  
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Figure AI-6. T1L but not T3Drv abrogates oral tolerance.  C57BL/6 mice were 
fed OVA every other day for 10 days. Some mice received T1L or T3Drv with 
OVA during the first feeding. Twenty-four hours after the last feeding, mice were 
primed with a subcutaneous injection of OVA in complete Freund’s adjuvant 
(CFA). Eight days post-injection with OVA/CFA, draining lymph nodes were 
resected, and cells were isolated and restimulated with OVA. IFNγ levels in the 
draining lymph node were quantifiedd by ELISA. IFNγ levels were normalized to 
the sham (non-tolerized) group for each experiment. Data represent the means 
of four independent experiments with 3 mice per treatment per experiment. Error 
bars represent standard error of the mean.  
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production in the lamina propria and intestinal epithelium compared with T3Drv 
(Figure AI-7). These findings suggest that T1L infection leads to inflammatory 
cytokine production in the intestine, which may potentiate a loss of oral tolerance 
in mice.  
 
Conclusions and Future Directions 
Summary 
Experiments presented in this chapter demonstrate that infection with T1L 
reovirus (Figure AI-6) or treatment with poly (I:C) (Figure AI-2), an analog of 
dsRNA, used as a model antagonist in pilot studies, abrogates oral tolerance 
induction in mice. Studies using poly (I:C) in mice lacking the type IFN receptor 
(Figure AI-3) suggest that this TLR3 agonist blocks formation of oral tolerance 
through the production of type 1 IFNs. Concordant with a function of IFN in 
tolerance abrogation, infection with T1L leads to higher levels of type 1 IFNs in 
the gut (Figure AI-7). Interestingly, T1L but not T3Drv abrogates oral tolerance in 
mice. While type 1 IFN induction by T1L and T3Drv is comparable in the Peyer’s 
patches, T1L induces higher levels of type 1 IFNs in the lamina propria and 
intestinal epithelium, suggesting that inflammation at these sites prevents a 
tolerogenic response to fed antigen. Moreover, poly (I:C) blocks the generation of 
inducible Tregs in vitro (Figure AI-4), raising the possibility that diminished Treg 
responses contribute to oral tolerance abrogation. Taken together, these 
experiments suggest that viral infection promotes an inflammatory environment in  
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Figure AI-7. T1L induces higher levels of type 1 IFNs in the lamina propria 
and intestinal epithelium than does T3Drv.  C57BL/6 mice were inoculated 
perorally with 1010 PFU of either T1L or T3Drv. Forty-eight hours post-
inoculation, the Peyer’s patches (A), lamina propria (B), and intestinal epithelium 
(C) were isolated. Levels of IFNα and IFNβ were assessed by quantitative PCR. 
Levels of target mRNAs were normalized to GAPDH, and the results are 
expressed relative to type 1 IFN transcripts found in mice treated with PBS 
vehicle control (sham). Error bars represent standard deviation. Results are from 
a representative experiment of 3 mice per experimental condition. 
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the gut, which prevents generation of Tregs and impedes tolerance to oral 
antigen (Figure AI-8).  
 
Future directions 
Experiments presented in this chapter revealed that T1L but not T3Drv 
has the capacity to block oral tolerance induction in mice (Figure AI-6). These 
viruses replicate with comparable efficiency in the MLN, Peyer’s patches, and 
intestine, suggesting that differences in viral replication do not account for 
differences in type 1 IFN induction and loss of oral tolerance. While T1L and 
T3Drv induce comparable levels of type 1 IFNs in the Peyer’s patches, T1L 
induces more T1 IFN than does T3Drv in the intestinal epithelium and lamina 
propria. This finding suggests that the virus-host interaction contributes to the 
development of oral tolerance. These viruses provide a framework to define viral 
determinants of oral tolerance abrogation. T1L and T3Drv both contain the T1L 
S1 and L2 genes, but they differ in expression of the other eight reovirus gene 
segments. Using reverse genetics, it is possible to generate a panel of 
reassortant viruses to identify gene segments that contribute to loss of tolerance 
to fed antigens (Table AI-1). It would be informative to quantify type 1 IFN 
production in the lamina propria and intestinal epithelium following infection with 
these reassortant strains and evaluate the capacity of these viruses to block oral 
tolerance induction in mice. Since functions of the reovirus gene products are  
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Figure AI-8. Model of reovirus-induced loss of oral tolerance. Reovirus 
infection promotes an inflammatory environment within the intestine. Reovirus 
may trigger  innate signaling pathways to activate dendritic cells, which in turn 
prime T cells to generate inflammatory CD4+ T cell subsets at the expense of 
regulatory T cell induction. Future experiments will determine whether infection 
promotes anti-OVA and autoantibody production following infection.  
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Name 
Parent T1L S1 S2 S3 S4 M1 M2 M3 L1 L2 L3 
Parent T3Drv S1 S2 S3 S4 M1 M2 M3 L1 L2 L3 
A S1 S2 S3 S4 M1 M2 M3 L1 L2 L3 
B S1 S2 S3 S4 M1 M2 M3 L1 L2 L3 
C S1 S2 S3 S4 M1 M2 M3 L1 L2 L3 
D S1 S2 S3 S4 M1 M2 M3 L1 L2 L3 
E S1 S2 S3 S4 M1 M2 M3 L1 L2 L3 
F S1 S2 S3 S4 M1 M2 M3 L1 L2 L3 
G  S1 S2 S3 S4 M1 M2 M3 L1 L2 L3 
H S1 S2 S3 S4 M1 M2 M3 L1 L2 L3 
 
Table AI-1. Panel of T1L and T3D-rv reassortants. Eight reassortant viruses 
were generated using reverse genetics. These viruses can be used to study viral 
determinants of reovirus-mediated oral tolerance abrogation. 
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well understood, such experiments will provide the first steps in defining 
mechanisms by which viral infections lead to loss of oral tolerance.  
The finding that T1L but not T3Drv abrogates oral tolerance in mice 
illustrates the concept that some but not all enteric viruses have the capacity to 
alter the immune response to dietary antigens. There is evidence to support this 
contention from studies of celiac disease patients. Persons with celiac disease 
display higher titers of adenovirus type 12-specific antibodies than controls, yet 
celiac disease cases and controls have comparable levels of antibodies to the 
related adenovirus type 18 (234, 246). In addition to reovirus, rotavirus (232), a 
double-stranded RNA virus virus, astrovirus (233), a positive-sense, single-
stranded RNA virus, and adenovirus (234, 246), a double-stranded DNA virus, 
are associated with celiac disease. These observations indicate that the genome 
type of the virus is insufficient to promote loss of oral tolerance.  
The mechanism by which certain viruses promote an inflammatory 
response to fed antigen is not understood. It would be useful to determine 
whether these viruses share any common properties. For example, adenovirus 
type 12 displays some sequence similarity to α-gliadin (246). In a specific region 
of the viral E1b protein, 8 of 12 amino acids are identical between adenovirus 12 
and α-gliadin, including 5 consecutive amino acids. Analysis of other eukaryotic, 
prokaryotic, and animal virus proteins did not reveal sequence similarities to that 
degree (246). It is unclear which animal viruses were included in the analysis. 
Sequences of rotavirus, reovirus, astrovirus, and adenovirus type 12 should be 
compared to each other and to gluten peptides to determine whether there is 
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sequence similarity. Alternatively, the immune response, particularly production 
of type 1 IFNs in intestinal epithelial cells or intestinal cell lines, could be 
assessed for T1L, T3Drv, adenovirus 12, and adenovirus 18. While adenovirus 
has only been correlated with celiac disease, it would be interesting to test 
whether T1L and adenovirus 12 induce similar immune signatures in comparison 
to those induced by T3Drv and adenovirus 18.  
Celiac disease is characterized by the presence of gluten-specific T cells 
and antibodies as well as antibodies against TG2. Experiments presented in this 
chapter examined the T cell arm of this disease. The effect of reovirus infection 
on antibody production is unknown. Using ELISAs, the levels of OVA-specific 
antibodies and TG2-specific antibodies in mice following peroral administration of 
T1L and OVA could be quantified to answer this question. 
Studies using poly (I:C) suggest that this analog of dsRNA blocks the 
generation of inducible regulatory T cells in vitro. These experiments should be 
repeated using T1L and T3Drv to determine whether reovirus also has the 
capacity to block Treg differentiation. It would be useful to determine whether this 
phenomenon also is observed in infected mice as well. Such experiments would 
enhance an understanding of the function of Tregs in virus-mediated abrogation 
of oral tolerance.  
Celiac disease is a gluten-sensitive enteropathy, and experiments 
presented in this chapter used OVA as a model antigen. OVA is a more 
convenient antigen to use because it can be easily administered and is not 
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included in standard mouse chow. Thus, the timing of antigen introduction into 
the diet can be manipulated as an experimental variable to facilitate development 
of a mouse model of celiac disease. Mice that lack expression of native MHC 
class II molecules but instead express human HLA-DQ8 are available. Our 
collaborators in the Jabri laboratory have maintained these mice on a gluten-free 
diet and introduced gluten orally in the presence and absence of reovirus 
infection. Mice that received gluten and T1L developed anti-gluten antibodies. 
These conditions also led to the activation of TG2 in the duodenum (Bouziat and 
Jabri, unpublished). It will be informative to perform similar oral tolerance 
experiments using gluten as the antigen to determine whether T1L induces 
gluten-specific T cells and villous atrophy. The possibility that T1L and T3Drv 
differ in induction of these phenotypes also should be assessed.  
A remaining question is whether reovirus infection has the capacity to 
break established tolerance to fed antigen. In my experiments, mice were 
inoculated with reovirus and fed OVA at the same time. While celiac disease is 
most prevalent in children, disease onset does not perfectly correlate with the 
introduction of gluten into the diet. Therefore, it would be useful to establish 
tolerance in mice by feeding low doses of either OVA or gluten every other day 
for ten days, wait one week, and then begin a second round of feeding in the 
presence or absence of T1L. Mice would then be primed 24 hours after the last 
feeding, and responses to the fed antigens would be assessed one week after 
the subcutaneous challenge.  
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Repeated viral infections are associated with increased rates of celiac 
disease in genetically susceptible persons (232). To determine whether multiple 
infections promote celiac disease pathology in mice, HLA-DQ8 mice could be 
maintained on a gluten-containing diet and repeatedly infected with reovirus. At 
certain intervals, mice could be euthanized, and the presence of gluten-specific T 
cells, gluten- and TG2-specific antibodies, TG2 activation, and villous atrophy 
could be assessed.  
I found it intriguing that some individuals with celiac disease, particularly 
those who manifest nervous system symptoms, contain anti-ganglioside 
antibodies (247-250). Some of these antibodies are directed against ganglioside 
GM2, which serves as a glycan receptor for serotype 1 reovirus (10) (Chapters 2-
5). One study examined the interaction of glaidin with ganglioside GM1 (251). 
Gliadin binds GM1 both in vitro and on the intestinal epithelium. It would be 
informative to determine whether GM2 also binds gliadin. One possibility is that 
reovirus and gliadin interact through mutual association with GM2. To test this 
hypothesis, wildtype or HLA-DQ8 mice could be inoculated with either T1L or a 
virus containing the S370P/Q371E mutations in σ1. If GM2-reovirus interactions 
are required for reovirus-mediated loss of oral tolerance, then T1L but not the 
mutant virus would abrogate tolerance induction and perhaps facilitate 
generation of anti-gliadin antibodies in mice.  
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Conclusions 
Experiments presented in this chapter demonstrate that infection with T1L 
but not T3Drv breaks immune tolerance to OVA as a model dietary antigen. This 
finding provides a tractable system that can be used to identify viral determinants 
of oral tolerance abrogation. Moreover, these studies, coupled with findings using 
HLA-DQ8-expressing mice in the Jabri laboratory (Bouziat and Jabri, 
unpublished), suggest that reovirus infection triggers pathology in mice that 
resembles celiac disease in humans. Moving forward, new studies inspired by 
this research will determine mechanisms of oral tolerance abrogation and 
investigate the contribution of reovirus infection to celiac disease onset in 
humans.  
 
Methods 
 
Medium 
RPMI 1640 (Gibco) was supplemented to contain 10% FBS (Gibco), 1% 
penicillin-streptomycin (Gibco), 5 μg/mL gentamicin, and 0.05 mM β-
mercaptoethanol (Sigma). Complete RPMI was used for most assays, except for 
isolation of the intestinal epithelial and lamina propria cells. 
Mice 
C57Bl/6 mice were purchased from Jackson Laboratory. IFNαβ-/- mice on 
a C57Bl/6 background were provided by Tatyana Golovkina (University of 
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Chicago). Mice at an age of 6-8 weeks were used for all experiments. T cells 
were isolated from FOXP3-eGFP mice as described (252, 253). All experiments 
were performed in accordance with the Institutional Biosafety Committees and 
Institutional Animal Care and Use Committees at the University of Chicago and 
Vanderbilt University.  
T cell isolation 
Spleens and peripheral lymph nodes from FOXP3-eGFP mice were 
isolated and mechanically disrupted by passage through a 70 μm cell strainer. 
CD4+ cells were isolated using CD4-specific microbeads (Miltenyi Biotech). 
FOXP3- CD4+ cells were isolated using a BD FACS Aria (BD Bioscience) as 
described (252). 
Splenic dendritic cell isolation 
Spleens were excised from wildtype C57Bl/6 mice, digested using 400 
U/ml of type IV collagenase (Sigma-Aldrich), and mechanically disrupted by 
passage through a 100 μm cell strainer. Cells were resuspended in an OptiPrep 
(Sigma-Aldrich) density gradient (252) and centrifuged at 700 x g for 30 min. 
CD11c+ dendritic cells were isolated using CD11c-specific magnetic beads 
(Miltenyi Biotech) according to the manufacturer’s instructions. 
In vitro regulatory T cell induction assay 
Wells of 96-well plates (Co-Star) were coated with 1 μg/ml of anti-CD3 
antibody (eBioscience) at 4ºC overnight. Plates were washed, and 105 
CD4+FOXP3- T cells were co-cultured with 4 x 104 splenic CD11C+ dendritic cells 
at 37ºC for 3 days in the presence and absence of recombinant TGFβ (2 μg/ml) 
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(R&D) and retinoic acid (10 nM) (Sigma-Aldrich) to induce regulatory T cells 
(DePaolo and Mucida Science 2007). Poly (I:C) (Invivogen) was added to some 
assays.  
Administration of oral antigen 
OVA (Sigma-Aldrich) was dissolved in PBS and administered by 
intragastric gavage using 18-20 gauge round-tipped needles. In some 
experiments, either poly (I:C) (10 μg) or reovirus (1010 PFU) was included in the 
inoculum. Mice were fed every other day for a total of five feedings. When used, 
poly (I:C) was included in every feeding, whereas reovirus was inoculated only 
during the first feeding, followed by four feedings with OVA alone.  
Analysis of the intestinal response to fed antigen 
Intestinal epithelial cells and lamina propria cells were isolated as 
described (252). The small intestine was resected and bisected longitudinally. 
Intestinal contents were removed by washing twice with PBS. The bisected 
intestine was divided into small pieces, resuspended in RPMI 1640 
supplemented to contain 1% dialyzed FBS (Gibco), 2 mM EDTA, and 1 mM 
MgCl2, and shaken at 37°C for 15 min. The supernatant was set aside, and the 
process was repeated with 15 mL of fresh medium. After the second incubation, 
cells were centrifuged at 500 x g for 5 min and resuspended in complete RPMI. 
Lamina propria cells were isolated from the remaining intestinal fragments using 
RPMI 1640 supplemented to contain 20% FBS and 100 U/mL of type VIII 
collagenase (Sigma). Samples were shaken at 37°C for 15 min. The supernatant 
was removed, and this process was repeated using fresh medium. The 
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supernatant from both incubations was centrifuged at 500 x g for 5 min. Cell 
pellets were resuspended in complete RPMI. The MLN and Peyer’s patches 
were excised and mechanically disrupted by passage through a 100 μm cell 
strainer. Cells were resuspended in complete RPMI and stimulated with 50 μg of 
OVA to detect antigen-specific cytokine responses. Cytokine levels in cell 
supernatants were analyzed by ELISA (BD Biosciences and eBioscience) 
according to the manufacturer’s instructions. Cytokine mRNA levels in cell pellets 
were analyzed by quantitative PCR (Life Technologies).  
Oral tolerance induction 
OVA (100 μg) was emulsified in a 1:1 ratio vol/vol of complete Freund’s 
adjuvant (CFA) and administered to mice via subcutanenous (50 μL) injection in 
the flanks 24 hours after the last dose of oral antigen was delivered. Eight days 
post-injection, mice were euthanized, the draining lymph nodes were removed, 
and single-cell suspensions were generated by mechanically disrupting the 
tissue and passage through a 100 μm cell strainer. Cells were resuspended at a 
density of 2 x 106/mL in complete RPMI and stimulated with OVA (50 μg) for 48 
hours. Supernatants were analyzed by ELISA (BD bioscience and eBioscience) 
according to the manufacturer’s instructions.  
T cell proliferation assays 
Following oral tolerance experiments, the draining lymph nodes were 
resected and mechanically disrupted by passage through a 70 μM filter and 
resuspended in complete RPMI at a concentration of 5 x 106 cells/mL. Cells in a 
volume of 100 μL were added to each each well of a 96-well plate. OVA protein 
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was suspended in PBS at a concentration of 1 mg/mL. Working dilutions of OVA 
ranging from 0 to 100 μg/mL were prepared using complete RPMI. Each dilution 
in a volume of 100 μL was added to cells. Cells were incubated at 37ºC for 48 h 
and then incubated with 1 μCi of 3H. Cells were incubated for an additional 18-24 
h and frozen. Counts per minute (CPM) were quantified using a liquid scintillation 
counter (University of Chicago).  
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